ELSEVIER

Journal of the Neurological Sciences 205 (2002) 95–106

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

Cumulative Author Index, Volumes 195–205 (2002)

Aarseth, J.H., see Myhr, K.-M. (202) 93
Abu-Katash, M., see Chapman, J. (203–204) 81
Adachi, Y., see Mori, M. (195) 149
Adamec, E., Murrell, J.R., Takao, M., Hobbs, W., Nixon, R.A., Ghetti, B. and Vonsattel, J.P.
P301L tauopathy confocal immunofluorescence study of perinuclear aggregation of the mutated protein (200) 85
Aharon-Peretz, J., Daskovski, E., Mashiach, T. and Tomer, R.
Natural history of dementia associated with lacunar infarctions (203–204) 53
Aizu, Y., see Wada, M. (200) 67
Akatsu, H., Takahashi, M., Matsukawa, N., Ishikawa, Y., Kondo, N., Sato, T., Nakazawa, H., Yamada, T., Okada, H., Yamamoto, T. and Kosaka, K.
Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital (196) 63
Akematsu, T., see Ohi, T. (197) 73
Akematsu, T., see Ohi, T. (201) 93
Akiba, S., see Ohkubo, R. (198) 31
Akkawi, N., see Borroni, B. (203–204) 189
Alaedini, A., Briani, C., Wirguin, I., Siciliano, G., D'Avino, C. and Latov, N.
Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay (196) 41
Alberti, A., see Sarchielli, P. (198) 9
Amenta, F., Mignini, F., Rabbia, F., Tomassoni, D. and Veglio, F.
Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data (203–204) 147
Andersson, M., see Gonzalez, H. (205) 9
Ando, Y., see Watanabe, H. (195) 63
Andreadou, E., see Evdokimidis, I. (195) 25
Anstrom, J.A., see Brown, W.R. (203–204) 159
Anstrom, J.A., see Challa, V.R. (203–204) 165
Anstrom, J.A., see Brown, W.R. (203–204) 169
Antonello, R.M., see Moretti, R. (203–204) 141
Antonini, G., see Mammarella, A. (201) 59
Arimura, K., see Okamoto, Y. (195) 71
Arimura, K., see Ohkubo, R. (198) 31
Arino, H., see Kato, N. (202) 69
Aschoff, A., see Bonelli, R.M. (203–204) 207
Assaf, Y., Mayzel-Oreg, O., Gigi, A., Ben-Bashat, D., Mordohovitch, M., Verchovsky, R., Reider-Groswasser, I.I., Hendler, T., Graif, M., Cohen, Y. and Korczyn, A.D.
High *b* value *q*-space-analyzed diffusion MRI in vascular dementia: A preliminary study (203–204) 235
Atsuchi, Y., see Ohkubo, R. (198) 31
Auchus, A.P., Chen, C.P.L.H., Sodagar, S.N., Thong, M. and Sng, E.C.S.
Single stroke dementia: Insights from 12 cases in Singapore (203–204) 85
Auchus, A.P., see Tham, W. (203–204) 49
Avgeropoulos, N., see Tyor, W.R. (200) 33
Axelrod, F.B., see Duëctsch, M. (195) 77
Axelrod, F.B., see Hilz, M.J. (196) 81
Ayuso, C., see Garcia Ruiz, P.J. (202) 59
Aziz, T., see Katzberg, H.D. (202) 77

Bagg, E., see Domínguez, R.O. (203–204) 67
Baier, P.C., Winkelmann, J., Höhne, A., Lancel, M. and Trenkwalder, C.
Assessment of spontaneously occurring periodic limb movements in sleep in the rat (198) 71
Bakshi, R., see Janardhan, V. (205) 51
Bakshi, R., see Dubey, N. (205) 77
Balabanov, R., see Wagnerova, J. (195) 51
Baron, P., see Conti, G. (195) 35
Baron, P., see Scarpini, E. (195) 41
Barone, R., Parano, E., Trifiletti, R.R., Fiumara, A. and Pavone, P.
White matter changes mimicking a leukodystrophy in a patient with Mucopolysaccharidosis: characterization by MRI (195) 171
Barreiro, P., see Frank, A. (203–204) 173
Bartolini, L., see Sarti, C. (203–204) 263
Bartolomé, E.L., see Domínguez, R.O. (203–204) 67
Bashir, K., see Jeffery, D. (201) 89
Basili, S., see Mammarella, A. (201) 59
Baudic, S., see Traykov, L. (203–204) 177
Bava, A., see Moretti, R. (203–204) 141
Bayazıt, N., see Yılmaz, M. (197) 69
Bayazıt, Y.A., Gürsoy, S., Özer, E., Karakurum, G. and Madenci, E.
Neurotologic manifestations of the fibromyalgia syndrome (196) 77
Bayazıt, Y.A., see Yılmaz, M. (197) 69
Bednarska-Makaruk, M., see Ryglewicz, D. (203–204) 195
Behari, M., see Shukla, G. (199) 55
Belaidi, H., see Benomar, A. (198) 25
Beley, A., see Demougeot, C. (199) 73
Ben-Bashat, D., see Assaf, Y. (203–204) 235
Bendtzen, K., see Christensen, H. (201) 1
Benomar, A., Yahyaoui, M., Meggouh, F., Bouhouche, A., Boutchich, M., Bouslam, N., Zaim, A., Schmitt, M., Belaidi, H., Ouazzani, R., Chkili, T. and Koenig, M.
Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families (198) 25
Bereczki, D., see Szatmári, S. (203–204) 99
Bergamasco, B., see Lopiano, L. (195) 167
Bergen, D.C. and World Federation of Neurology Task Force on Neurological Services,
Training and distribution of neurologists worldwide (198) 3
Berger, F.M., see Frölich, L. (203–204) 137
Bernsen, R.A.J.A.M., De Jager, A.E.J., Schmitz, P.I.M. and Van der Meché, F.G.A.
Long-term impact on work and private life after Guillain–Barré syndrome (201) 13
Berzin, T., see Salloway, S. (203–204) 183
Bethke, F., see Ellger, T. (205) 35
Bhardwaj, A., see Geocadin, R.G. (205) 29
Bhatia, M., see Shukla, G. (199) 55

PII: S0022-510X(02)00406-9

Bi, H. and Sze, C.-I.
N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease (200) 11
Biaggioni, I., see Parikh, S.M. (200) 1
Bianchi, R., see Conti, G. (195) 35
Bigalke, H., see Blersch, W. (205) 59
Birbeck, G.L. and Munsat, T.
Neurologic services in Sub-Saharan Africa: a case study among Zambian primary healthcare workers (200) 75
Bird, T.D., see Chen, D.-H. (196) 91
Birkner, T., see Terborg, C. (205) 71
Blersch, W., Schulte-Mattler, W.J., Przywara, S., May, A., Bigalke, H. and Wohlfarth, K.
Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study (205) 59
Blumberg, B., see Ming, X. (197) 9
Blumhardt, L.D., see Vaithianathar, L. (197) 45
Boller, F., see Traykov, L. (203–204) 177
Bonelli, R.M., Aschoff, A. and Jirikowski, G.
Cerebrospinal fluid tissue transglutaminase in vascular dementia (203–204) 207
Boneschi, F.M., see Del Bo, R. (202) 85
Bönöczk, P., see Vas, Á. (203–204) 259
Bordoni, A., see Del Bo, R. (202) 85
Borg, K., see Gonzalez, H. (205) 9
Borroni, B., Akkawi, N., Martini, G., Colciaghi, F., Prometti, P., Rozzini, L., Di Luca, M., Lenzi, G.L., Romanelli, G., Caimi, L. and Padovani, A.
Microvascular damage and platelet abnormalities in early Alzheimer's disease (203–204) 189
Bouhouche, A., see Benomar, A. (198) 25
Bouslam, N., see Benomar, A. (198) 25
Boutchich, M., see Benomar, A. (198) 25
Bowirrat, A., Friedland, R.P. and Korczyn, A.D.
Vascular dementia among elderly Arabs in Wadi Ara (203–204) 73
Bowler, J.V.
The concept of vascular cognitive impairment (203–204) 11
Boyle, P., see Salloway, S. (203–204) 227
Boysen, G., see Christensen, H. (201) 1
Braeske, K., see Hilz, M.J. (196) 81
Bramer, S., see Terborg, C. (205) 15
Bresolin, N., see Del Bo, R. (202) 85
Briani, C., see Alaedini, A. (196) 41
Brown, W.R., Moody, D.M., Challa, V.R., Thore, C.R. and Anstrom, J.A.
Venous collagenosis and arteriolar tortuosity in leukoaraiosis (203–204) 159
Brown, W.R., Moody, D.M., Challa, V.R., Thore, C.R. and Anstrom, J.A.
Apoptosis in leukoaraiosis lesions (203–204) 169
Brown, W.R., see Challa, V.R. (203–204) 165
Brunotte, F., see Demougeot, C. (199) 73
Buchheister, A., see Ellger, T. (205) 35
Buchwald, L., see Jeffery, D. (201) 89
Bullido, M.J., see Frank, A. (203–204) 173

Caimi, L., see Borroni, B. (203–204) 189
Cantarero, S., see Garcia Ruiz, P.J. (202) 59
Capra, R., see Mattioli, F. (195) 161
Cardozo, A., see Muñoz, E. (200) 19
Carton, H., see Nelissen, I. (200) 43
Cavalheiro, E.A., see Sinigaglia-Coimbra, R. (203–204) 273
Cazzato, G., see Moretti, R. (203–204) 141
Cervenakova, L., see Wagnerova, J. (195) 51
Challa, V.R., Thore, C.R., Moody, D.M., Brown, W.R. and Anstrom, J.A.
A three-dimensional study of brain string vessels using celloidin sections stained with anti-collagen antibodies (203–204) 165
Challa, V.R., see Brown, W.R. (203–204) 159
Challa, V.R., see Brown, W.R. (203–204) 169
Chang, D.-C., see Lin, J.-J. (199) 25
Chang, H.-M., see Tham, W. (203–204) 49
Chapman, J., Abu-Katash, M., Inzelberg, R., Yust, I., Neufeld, M.Y., Vardinon, N., Treves, T.A. and Korczyn, A.D.
Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants (203–204) 81
Chaturvedi, S., see Kudesia, R. (202) 25
Chaudhary, G., see Gupta, Y.K. (203–204) 267
Chen, C.P.L.-H., see Tham, W. (203–204) 49
Chen, C.P.L.H., see Auchus, A.P. (203–204) 85
Chen, D.-H., Lipe, H.P., Qin, Z. and Bird, T.D.
Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity (196) 91
Chen, J., Li, Y., Wang, L., Lu, M. and Chopp, M.
Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats (199) 17
Chen, M., Conway, K., Johnson, K.P., Martin, R. and Dhib-Jalbut, S.
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years (201) 71
Chey, J., see Cho, B. (203–204) 109
Chiari, S., see Mattioli, F. (195) 161
Chkili, T., see Benomar, A. (198) 25
Cho, B., Yang, J., Kim, S.Y., Yang, D.W., Park, M. and Chey, J.
The validity and reliability of a Computerized Dementia Screening Test developed in Korea (203–204) 109
Chopp, M., see Chen, J. (199) 17
Chowdhury, M., see Meyer, J.S. (201) 19
Christensen, E., see Christensen, H. (201) 1
Christensen, H., Boysen, G., Johannesen, H.H., Christensen, E. and Bendtzen, K.
Deteriorating ischaemic stroke cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke (201) 1
Clerici, R., see Scarpini, E. (195) 41
Codella, M., see Mattioli, F. (195) 161
Cohen, Y., see Assaf, Y. (203–204) 235
Coimbra, C., see Sinigaglia-Coimbra, R. (203–204) 273
Colciaghi, F., see Borroni, B. (203–204) 189
Comi, G., see Rovaris, M. (195) 103
Comi, G.P., see Del Bo, R. (202) 85
Constantinidis, T.S., see Evdokimidis, I. (195) 25
Conti, G., Scarpini, E., Baron, P., Livraghi, S., Tiriticco, M., Bianchi, R., Vedeler, C. and Scarlato, G.
Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1β and p75NTR (195) 35
Conti, G., see Scarpini, E. (195) 41
Conway, K., see Chen, M. (201) 71
Cook, S.D., see Ming, X. (197) 9
Cornish, A., see Proukakis, C. (201) 65
Correia, S., see Salloway, S. (203–204) 183, 227
Costes-Salon, M.-C., see Traon, A.P.-L. (195) 139
Costes-Salon, M.-C., see Traon, A.P.-L. (201) 91
Coyle, P., see Jeffery, D. (201) 89
Crimi, M., see Del Bo, R. (202) 85
Crosby, A.H., see Proukakis, C. (201) 65
Croul, S., see Hansrote, S. (197) 63
Csiba, L., see Szatmári, S. (203–204) 99

Csiba, L., see Vas, Á. (203–204) 259
Culver, D.G., see Glass, J.D. (196) 9
Cwik, V.A., see Hanstock, C.C. (198) 37
Członkowska, A., Niewada, M., Saleh El-Baroni, I., Mendel, T., Ryglewicz, D., Sandercock, P. and Lewis, S.
High early case fatality after ischaemic stroke in Poland: Exploration of possible explanations in the International Stroke Trial (202) 53

D'Abbraccio, G., see Domínguez, R.O. (203–204) 67
Dahl, H.-H.M., see Lewis, S. (201) 39
Daskovski, E., see Aharon-Peretz, J. (203–204) 53
D'Avino, C., see Alaedini, A. (196) 41
De Baets, M. and Stassen, M.H.W.
The role of antibodies in myasthenia gravis (202) 5
Deguchi, K., Sasaki, I., Tsukaguchi, M., Kamoda, M., Touge, T., Takeuchi, H. and Kuriyama, S.
Abnormalities of rate-corrected QT intervals in Parkinson's disease—a comparison with multiple system atrophy and progressive supranuclear palsy (199) 31
De Jager, A.E.J., see Bernsen, R.A.J.A.M. (201) 13
Del Bene, M., see Naini, A. (198) 17
Del Bo, R., Bordoni, A., Boneschi, F.M., Crimi, M., Sciacco, M., Bresolin, N., Scarlato, G. and Comi, G.P.
Evidence and age-related distribution of mtDNA D-loop point mutations in skeletal muscle from healthy subjects and mitochondrial patients (202) 85
Demetriades, A.K.
Functional neuroimaging in Alzheimer's type dementia (203–204) 247
Demougeot, C., Walker, P., Beley, A., Marie, C., Rouaud, O., Giroud, M. and Brunotte, F.
Spectroscopic data following stroke reveal tissue abnormality beyond the region of T2-weighted hyperintensity (199) 73
De Seze, J., Stojkovic, T., Ferriby, D., Gauvrit, J.-Y., Montagne, C., Mounier-Vehier, F., Verier, A., Pruvo, J.-P., Hache, J.-C. and Vermersch, P.
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile (197) 57
Dhib-Jalbut, S., see Chen, M. (201) 71
Dichgans, M.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: Phenotypic and mutational spectrum (203–204) 77
Diederich, N.J., see Pieri, V. (205) 87
Diedrich, A., see Parikh, S.M. (200) 1
Díez-Tejedor, E., see Frank, A. (203–204) 173
Di Luca, M., see Borroni, B. (203–204) 189
Domina, E., see Le Pira, F. (201) 53
Domínguez, R.O., Marschoff, E.R., Serra, J.A., Gallo, A., Bartolomé, E.L., González, S., D'Abbraccio, G., Bagg, E., Vila, J. and Famulari, A.L.
Stroke vs. chronic progressive cerebrovascular disease: A magnetic resonance imaging study of symptomatic outpatients (203–204) 67
Dore-Duffy, P., see Wagnerova, J. (195) 51
Dowling, P.C., see Ming, X. (197) 9
Doyu, M., see Watanabe, H. (195) 63
Du, X.-J., see Lambert, E. (198) 43
Dubas, F., see Fressinaud, C. (196) 53
Dubey, N., Miletich, R.S., Wasay, M., Mechtler, L.L. and Bakshi, R.
Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis (205) 77
Dubois, B., see Nelissen, I. (200) 43
Duëctsch, M., Hilz, M.J., Rauhut, U., Solomon, J., Neundörfer, B. and Axelrod, F.B.
Sympathetic and parasympathetic pupillary dysfunction in familial dysautonomia (195) 77
Dziedzic, T., see Slowik, A. (196) 27

Eguchi, K., see Fujimoto, T. (196) 21
Eisdorfer, C., see Minagar, A. (202) 13
Ellger, T., Bethke, F., Frese, A., Luettmann, R.J., Buchheister, A., Ringelstein, E.B. and Evers, S.
Event-related potentials in different subtypes of multiple sclerosis—a cross-sectional study (205) 35
Ellul, J., see Polychronopoulos, P. (195) 117
Enzinger, C., see Schmidt, R. (203–204) 253
Erkinjuntti, T.
Treatment options: The latest evidence with galantamine (Reminyl®) (203–204) 125
Evdokimidis, I., Constantinidis, T.S., Gourtzelidis, P., Smyrnis, N., Zalonis, I., Zis, P.V., Andreadou, E. and Papageorgiou, C.
Frontal lobe dysfunction in amyotrophic lateral sclerosis (195) 25
Evers, S., see Ellger, T. (205) 35

Falautano, M., see Rovaris, M. (195) 103
Fallon, J., see Salloway, S. (203–204) 183
Famulari, A.L., see Domínguez, R.O. (203–204) 67
Fazekas, F., see Schmidt, R. (203–204) 253
Fekete, I., see Szatmári, S. (203–204) 99
Fellner, C., see Hecht, M.J. (199) 59
Fellner, F., see Hecht, M.J. (199) 59
Ferrer, I., see Muñoz, E. (200) 19
Ferriby, D., see De Seze, J. (197) 57
Ferro, J.M. and Madureira, S.
Age-related white matter changes and cognitive impairment (203–204) 221
Ferroni, P., see Mammarella, A. (201) 59
Fidziańska, A.
''Cap disease''—a failure in the correct muscle fibre formation (201) 27
Filippi, M., see Rovaris, M. (195) 103
Filippi, M., see Mattioli, F. (195) 161
Fillit, H. and Hill, J.
The costs of vascular dementia: A comparison with Alzheimer's disease (203–204) 35
Fiumara, A., see Barone, R. (195) 171
Flechter, S., Vardi, J., Pollak, L. and Rabey, J.M.
Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up (197) 51
Floridi, A., see Sarchielli, P. (198) 9
Forette, F., see Traykov, L. (203–204) 177
Fourcade, J., see Traon, A.P.-L. (195) 139
Fourcade, J., see Traon, A.P.-L. (201) 91
Frank, A., Díez-Tejedor, E., Bullido, M.J., Valdivieso, F. and Barreiro, P.
APOE genotype in cerebrovascular disease and vascular dementia (203–204) 173
Freedman, M., see Jeffery, D. (201) 89
Frese, A., see Ellger, T. (205) 35
Fressinaud, C., Vigneron, I., Letournel, F., Nicolas, G., Jean, I. and Dubas, F.
Cytoskeleton abnormalities in axonopathies of unknown aetiology: correlations with morphometry (196) 53
Friedland, R.P., see Bowirrat, A. (203–204) 73
Frisoni, G.B., see Geroldi, C. (203–204) 241
Frölich, L., Klinger, T. and Berger, F.M.
Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease (203–204) 137
Fujikawa, K., see Kato, N. (202) 69
Fujimoto, S., Hasegawa, Y., Yokota, C., Tagaya, M., Hayashida, K., Yamaguchi, T. and Minematsu, K.
Acetazolamide challenge test using semiquantitative ^{123}I-IMP SPECT for detection of cerebral misery perfusion (205) 21

Fujimoto, T., Nakamura, T., Nishiura, Y., Ichinose, K., Furuya, T., Shirabe, S. and Eguchi, K.
Up-regulation of interleukin-12 receptor expression in peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (196) 21
Fujimura, R., see Minagar, A. (202) 13
Fujiyama, J., see Hamano, T. (199) 45
Fukazawa, T., see Kikuchi, S. (205) 47
Fukui, T., see Ishihara, K. (198) 97
Fukutake, T., see Onodera, M. (205) 83
Furukawa, S., see Murakami, Y. (198) 63
Furuya, H., see Ochi, H. (201) 45
Furuya, T., see Fujimoto, T. (196) 21

Galimberti, D., see Scarpini, E. (195) 41
Galinier, M., see Traon, A.P.-L. (195) 139
Galinier, M., see Traon, A.P.-L. (201) 91
Gallai, V., see Sarchielli, P. (198) 9
Gallo, A., see Domínguez, R.O. (203–204) 67
Galluzzi, S., see Geroldi, C. (203–204) 241
Gan, R., see Yu, R.F. (199) 49
Gandelman-Marton, R., see Klein, C. (200) 63
Garcia Ruiz, P.J., Mayo, D., Hernandez, J., Cantarero, S. and Ayuso, C.
Movement disorders in hereditary ataxias (202) 59
Gauvrit, J.-Y., see De Seze, J. (197) 57
Gazzaniga, P.P., see Mammarella, A. (201) 59
Geerts, H., see Grantham, C. (203–204) 131
Geocadin, R.G., Razumovsky, A.Y., Wityk, R.J., Bhardwaj, A. and Ulatowski, J.A.
Intracerebral hemorrhage and postpartum cerebral vasculopathy (205) 29
Geroldi, C., Galluzzi, S., Miao, J., Testa, C. and Frisoni, G.B.
Development of a CT-based weighted rating scale for subcortical cerebrovascular disease sensitive to mild clinical symptoms (203–204) 241
Ghetti, B., see Adamec, E. (200) 85
Gigi, A., see Assaf, Y. (203–204) 235
Gioldasis, G., see Polychronopoulos, P. (195) 117
Giroud, M., see Demougeot, C. (199) 73
Giuffrida, S., see Restivo, D.A. (198) 87
Giuffrida, S., see Le Pira, F. (201) 53
Glass, D., see Salloway, S. (203–204) 183
Glass, J.D., Culver, D.G., Levey, A.I. and Nash, N.R.
Very early activation of m-calpain in peripheral nerve during Wallerian degeneration (196) 9
Goetz, C.G., see Pieri, V. (205) 87
Goh, M.-L., see Tham, W. (203–204) 49
Gonzalez, H., Khademi, M., Andersson, M., Wallström, E., Borg, K. and Olsson, T.
Prior poliomyelitis-evidence of cytokine production in the central nervous system (205) 9
González, S., see Domínguez, R.O. (203–204) 67
Goris, A., see Nelissen, I. (200) 43
Gorman, M.J.
Multiple sclerosis presenting as ataxic hemiparesis (197) 85
Gourtzelidis, P., see Evdokimidis, I. (195) 25
Graban, A., see Ryglewicz, D. (203–204) 195
Graif, M., see Assaf, Y. (203–204) 235
Grantham, C. and Geerts, H.
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease (203–204) 131
Gregorini, G., see Mattioli, F. (195) 161
Grewal, R.P., see Zumo, L. (195) 47
Gulyás, B., see Vas, Á. (203–204) 259
Gupta, R.K., see Kalita, J. (198) 21
Gupta, Y.K., Sinha, K. and Chaudhary, G.
Transient focal ischemia induces motor deficit but does not impair the cognitive function in middle cerebral artery occlusion model of stroke in rats (203–204) 267
Gur, T., see Salloway, S. (203–204) 183
Gürsoy, S., see Bayazıt, Y.A. (196) 77
Gyrd-Hansen, M., Krag, T.O.B., Rosmarin, A.G. and Khurana, T.S.
Sp1 and the *ets*-related transcription factor complex GABPα/β functionally cooperate to activate the utrophin promoter (197) 27

Hache, J.-C., see De Seze, J. (197) 57
Hämäläinen, P., see Seinelä, A. (198) 79
Hamano, T., Fujiyama, J., Kawamura, Y., Hirayama, M., Ito, K., Inagaki, T., Kumano, T., Mutoh, T. and Kuriyama, M.
Muscle MRI findings of HTLV-1-associated myelopathy (199) 45
Hansrote, S., Croul, S., Selak, M., Kalman, B. and Schwartzman, R.J.
External ophthalmoplegia with severe progressive multiorgan involvement associated with the mtDNA A3243G mutation (197) 63
Hanstock, C.C., Cwik, V.A. and Martin, W.R.W.
Reduction in metabolite transverse relaxation times in amyotrophic lateral sclerosis (198) 37
Hart, P.E., see Proukakis, C. (201) 65
Hasegawa, Y., see Fujimoto, S. (205) 21
Hashimoto, N., see Ikeda, A. (202) 43
Hashizume, Y., see Konagaya, M. (195) 123
Hattori, H., see Tsutada, T. (198) 51
Hattori, N., see Watanabe, H. (195) 63
Hattori, T., see Kuwabara, S. (199) 89
Hattori, T., see Mori, M. (201) 85
Hattori, T., see Onodera, M. (205) 83
Häusler, M., Schaade, L., Kemény, S., Schweizer, K., Schoenmackers, C. and Ramaekers, V.Th.
Encephalitis related to primary varicella-zoster virus infection in immunocompetent children (195) 111
Hawkins, S.A., see McDonnell, G.V. (199) 1
Hayashida, K., see Fujimoto, S. (205) 21
Hayes, L., see Naini, A. (198) 17
Hecht, M.J., Fellner, F., Fellner, C., Hilz, M.J., Neundörfer, B. and Heuss, D.
Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: A follow-up examination including FLAIR images (199) 59
Hendler, T., see Assaf, Y. (203–204) 235
Hernandez, J., see Garcia Ruiz, P.J. (202) 59
Heuss, D., see Hecht, M.J. (199) 59
Heyes, M., see Minagar, A. (202) 13
Hilgenfeldt, U., see Wagner, S. (202) 75
Hill, J., see Fillit, H. (203–204) 35
Hilz, M.J., Axelrod, F.B., Braeske, K. and Stemper, B.
Cold pressor test demonstrates residual sympathetic cardiovascular activation in familial dysautonomia (196) 81
Hilz, M.J., see Duëctsch, M. (195) 77
Hilz, M.J., see Hecht, M.J. (199) 59
Hirai, S., see Isozaki, E. (197) 37
Hirata, K., see Okamoto, Y. (195) 71
Hirata, K., see Susuki, K. (195) 145
Hirayama, M., see Hamano, T. (199) 45
Hirono, N., see Hosaka, K. (199) 67
Hirono, N., see Sakamoto, S. (200) 27
Hobbs, W., see Adamec, E. (200) 85
Hogan, E.L., see Moran, A.P. (196) 1
Hogan, E.L., see Tyor, W.R. (200) 33
Höhne, A., see Baier, P.C. (198) 71
Horiuchi, I., see Ochi, H. (201) 45

Hosaka, K., Ishii, K., Sakamoto, S., Mori, T., Sasaki, M., Hirono, N. and Mori, E.
Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration (199) 67
Hosaka, K., see Sakamoto, S. (200) 27
Hovanesian, V., see Salloway, S. (203–204) 183
Hu, J., see Wada, M. (200) 67
Hulette, C., see Salloway, S. (203–204) 183
Hüll, M., see Schmidtke, K. (203–204) 17
Huoponen, K., see Puomila, A. (205) 41
Hutchison, W., see Lewis, S. (201) 39

Iannucci, G., see Rovaris, M. (195) 103
Ibadin, O.M., see Ofovwe, G.E. (200) 49
Ichinose, K., see Fujimoto, T. (196) 21
Ida, H., see Mikami, T. (199) 39
Ikeda, A., Sato, T., Ohara, S., Matsuhashi, M., Yamamoto, J., Takayama, M., Matsumoto, R., Mikuni, N., Takahashi, J., Miyamoto, S., Taki, W., Hashimoto, N. and Shibasaki, H.
''Supplementary motor area (SMA) seizure'' rather than ''SMA epilepsy'' in optimal surgical candidates: a document of subdural mapping (202) 43
Ikeda, H., see Tsutada, T. (198) 51
Ikeda, K.-i., see Ohkubo, R. (198) 31
Im, J.-H., see Oh, S.-H. (200) 57
Imafuku, I., see Yoshimura, M. (197) 89
Inagaki, T., see Hamano, T. (199) 45
Inzelberg, R., see Chapman, J. (203–204) 81
Inzitari, D., see Sarti, C. (203–204) 263
Iseki, E., Takayama, N., Marui, W., Uéda, K. and Kosaka, K.
Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains (195) 85
Iseki, E., see Marui, W. (195) 153
Ishida, A., see Mikami, T. (199) 39
Ishida, K., see Owada, K. (197) 79
Ishihara, K., Nonaka, A., Fukui, T., Kawamura, M., Shiota, J.-i. and Nakano, I.
Lewy body-free nigral degeneration—a case report (198) 97
Ishii, K., see Hosaka, K. (199) 67
Ishii, K., see Kawachi, T. (199) 79
Ishii, K., see Sakamoto, S. (200) 27
Ishikawa, Y., see Akatsu, H. (196) 63
Iso-o, N., see Yoshimura, M. (197) 89
Isozaki, E., Naito, R., Kanda, T., Mizutani, T. and Hirai, S.
Different mechanism of vocal cord paralysis between spinocerebellar ataxia (SCA 1 and SCA 3) and multiple system atrophy (197) 37
Ito, K., see Hamano, T. (199) 45
Ito, M., see Naito, E. (201) 33
Itzhaki, A., see Klein, C. (200) 63
Iversen, B.S., see Panayi, A.E. (195) 1
Iwaki, T., see Ohi, T. (197) 73
Iwaki, T., see Ohi, T. (201) 93

Jain, J.C., see Srivastava, R.A.K. (196) 45
Jakubowska, T., see Lojkowska, W. (203–204) 215
Janardhan, V. and Bakshi, R.
Quality of life in patients with multiple sclerosis: The impact of fatigue and depression (205) 51
Japan, S.M., see Ohi, T. (201) 93
Jean, I., see Fressinaud, C. (196) 53
Jedrzejczak, T., see Lojkowska, W. (203–204) 215
Jeffery, D., Bashir, K., Buchwald, L., Coyle, P., Freedman, M., Markowitz, C., Rammohan, K., Reder, T., Sharief, M. and (USA), J.W.
Optimizing immunomodulatory therapy for MS patients: an integrated management model (201) 89
Jeffery, D.R.
Early intervention with immunomodulatory agents in the treatment of multiple sclerosis (197) 1
Jellinger, K.A.
The pathology of ischemic-vascular dementia: An update (203–204) 153
Jirikowski, G., see Bonelli, R.M. (203–204) 207
Johannesen, H.H., see Christensen, H. (201) 1
Johnson, K.P., see Chen, M. (201) 71
Jonosono, M., see Okamoto, Y. (195) 71

Kahl, K.G., Kruse, N., Toyka, K.V. and Rieckmann, P.
Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis (200) 53
Kaji, M., see Sato, Y. (202) 65
Kalaria, R.
Similarities between Alzheimer's disease and vascular dementia (203–204) 29
Kalb, P., see Wagner, S. (202) 75
Kalita, J., Mishra, V.N., Misra, U.K. and Gupta, R.K.
Clinicoradiological observation in three patients with suicidal hanging (198) 21
Kalman, B., see Hansrote, S. (197) 63
Kamakura, K., see Tanaka, M. (201) 9
Kamata, M., see Wada, M. (200) 67
Kamitsukasa, I., see Onodera, M. (205) 83
Kamoda, M., see Deguchi, K. (199) 31
Kamondi, A., see Szirmai, I. (203–204) 91
Kanazawa, I., see Saito, Y. (196) 71
Kanazawa, I., see Yoshimura, M. (197) 89
Kanda, T., see Isozaki, E. (197) 37
Kanesaka, T., see Mori, M. (201) 85
Kanlıkama, M., see Yılmaz, M. (197) 69
Kapeller, P., see Schmidt, R. (203–204) 253
Karakurum, G., see Bayazıt, Y.A. (196) 77
Kárpáti, E., see Vas, Á. (203–204) 259
Kashiwaya, Y., see Mori, M. (195) 149
Kato, M., see Marui, W. (195) 153
Kato, M., see Yasuda, T. (197) 19
Kato, N., Nemoto, K., Arino, H. and Fujikawa, K.
Treatment of the chronic inflammation in peripheral target tissue improves the crushed nerve recovery in the rat: Histopathological assessment of the nerve recovery (202) 69
Kato, N., see Kuwabara, S. (199) 89
Katzberg, H.D., Aziz, T. and Oger, J.
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes (202) 77
Kawachi, T., Ishii, K., Sakamoto, S., Matsui, M., Mori, T. and Sasaki, M.
Gender differences in cerebral glucose metabolism: a PET study (199) 79
Kawamura, M., see Ishihara, K. (198) 97
Kawamura, Y., see Hamano, T. (199) 45
Kemény, S., see Häusler, M. (195) 111
Khademi, M., see Gonzalez, H. (205) 9
Khurana, T.S., see Gyrd-Hansen, M. (197) 27
Kikuchi, S., Niino, M., Fukazawa, T., Yabe, I. and Tashiro, K.
An assessment of the association between IL-2 gene polymorphisms and Japanese patients with multiple sclerosis (205) 47
Kim, B.-S., see Yang, D.-W. (203–204) 199
Kim, E.-N., see Yang, D.-W. (203–204) 199
Kim, S.-Y., see Yang, D.-W. (203–204) 199
Kim, S.Y., see Cho, B. (203–204) 109
Kimiagar, I., see Klein, C. (200) 63
Kira, J.-i., see Taniwaki, T. (200) 79
Kira, J.-i., see Ochi, H. (201) 45
Kiss, B., see Vas, Á. (203–204) 259

Klein, C., Kimiagar, I., Pollak, L., Gandelman-Marton, R., Itzhaki, A., Milo, R. and Rabey, J.M.
Neurological features of West Nile Virus infection during the 2000 outbreak in a regional hospital in Israel (200) 63
Klinger, T., see Frölich, L. (203–204) 137
Kobayashi, T., see Watanabe, H. (195) 63
Kodama, T., see Ohkubo, R. (198) 31
Koenig, M., see Benomar, A. (198) 25
Koga, M., see Kuwabara, S. (199) 89
Koga, M., see Onodera, M. (205) 83
Kohno, Y., see Yoshizawa, T. (195) 129
Koivisto, M., see Seinelä, A. (198) 79
Komai, K., see Ono, K. (199) 93
Konagaya, M., Konagaya, Y., Sakai, M., Matsuoka, Y. and Hashizume, Y.
Progressive cerebral atrophy in multiple system atrophy (195) 123
Konagaya, Y., see Konagaya, M. (195) 123
Kondo, I., see Sato, Y. (202) 65
Kondo, N., see Akatsu, H. (196) 63
Korczyn, A.D.
The complex nosological concept of vascular dementia (203–204) 3
Korczyn, A.D., see Bowirrat, A. (203–204) 73
Korczyn, A.D., see Chapman, J. (203–204) 81
Korczyn, A.D., see Assaf, Y. (203–204) 235
Koroshetz, W.J., see Singhal, A.B. (196) 37
Kosaka, K., see Iseki, E. (195) 85
Kosaka, K., see Marui, W. (195) 153
Kosaka, K., see Akatsu, H. (196) 63
Kougo, K., see Nanri, K. (198) 93
Kozlowicz-Gudzinska, I., see Lojkowska, W. (203–204) 215
Krag, T.O.B., see Gyrd-Hansen, M. (197) 27
Krishnan, K.R.R., see Salloway, S. (203–204) 227
Kruse, N., see Kahl, K.G. (200) 53
Kudesia, R. and Chaturvedi, S.
Practice variation among Michigan neurologists in the use of intravenous heparin (202) 25
Kumano, T., see Hamano, T. (199) 45
Kunicki, P.K., see Ryglewicz, D. (203–204) 195
Kuo, J.-S., see Wang, Y.-C. (202) 35
Kuo-Leblanc, V., see Salloway, S. (203–204) 183
Kurihara, S., see Mori, M. (195) 149
Kuriyama, M., see Hamano, T. (199) 45
Kuriyama, S., see Deguchi, K. (199) 31
Kuroda, Y., see Naito, E. (201) 33
Kusumi, M., see Mori, M. (195) 149
Kuwabara, S., Nakata, M., Sung, J.-Y., Mori, M., Kato, N., Hattori, T., Koga, M. and Yuki, N.
Hyperreflexia in axonal Guillain–Barré syndrome subsequent to *Campylobacter jejuni* enteritis (199) 89
Kuwabara, S., see Susuki, K. (195) 145
Kuwabara, S., see Mori, M. (201) 85
Kuwabara, S., see Onodera, M. (205) 83
Kuwabara, Y., see Taniwaki, T. (200) 79
Kwak, S., see Yoshimura, M. (197) 89

La Bella, V., see Militello, A. (195) 67
Lai, S.-C., see Wang, Y.-C. (202) 35
Lambert, E., Du, X.-J., Percy, E. and Lambert, G.
Cardiac response to norepinephrine and sympathetic nerve stimulation following experimental subarachnoid hemorrhage (198) 43
Lambert, G., see Lambert, E. (198) 43
Lancel, M., see Baier, P.C. (198) 71
Lanotte, M., see Lopiano, L. (195) 167
Lanza, S., see Restivo, D.A. (198) 87
Larrue, V., see Traon, A.P.-L. (195) 139
Larrue, V., see Traon, A.P.-L. (201) 91
Latov, N., see Alaedini, A. (196) 41
Lavretsky, H., see Salloway, S. (203–204) 227
Lee, K.-Y., see Oh, S.-H. (200) 57
Lee, M.-S., see Oh, S.-H. (200) 57
Lekka, N.P., see Polychronopoulos, P. (195) 117
Lenzi, G.L., see Borroni, B. (203–204) 189
Le Pira, F., Zappalà, G., Saponara, R., Domina, E., Restivo, D.A., Reggio, E., Nicoletti, A. and Giuffrida, S.
Cognitive findings in spinocerebellar ataxia type 2: relationship to genetic and clinical variables (201) 53
Letournel, F., see Fressinaud, C. (196) 53
Levey, A.I., see Glass, J.D. (196) 9
Lewis, S., Hutchison, W., Thyagarajan, D. and Dahl, H.-H.M.
Clinical and molecular features of adPEO due to mutations in the Twinkle gene (201) 39
Lewis, S., see Członkowska, A. (202) 53
Li, W., see Ming, X. (197) 9
Li, Y., see Chen, J. (199) 17
Lilienfeld, S., see O'Brien, J. (203–204) 41
Lin, C.-W., see Wang, Y.-C. (202) 35
Lin, J.-J., Yueh, K.-C., Chang, D.-C. and Lin, S.-Z.
Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease (199) 25
Lin, S.-Z., see Lin, J.-J. (199) 25
Lin, X., see Vaithianathar, L. (197) 45
Lindman, R. and Stål, P.S.
Abnormal palatopharyngeal muscle morphology in sleep-disordered breathing (195) 11
Lipe, H.P., see Chen, D.-H. (196) 91
Livraghi, S., see Conti, G. (195) 35
Lodder, J., see Rasquin, S.M.C. (203–204) 115
Lojkowska, W., see Ryglewicz, D. (203–204) 195
Lojkowska, W., Ryglewicz, D., Jedrzejczak, T., Sienkiewicz-Jarosz, H., Minc, S., Jakubowska, T. and Kozlowicz-Gudzinska, I.
SPECT as a diagnostic test in the investigation of dementia (203–204) 215
Lopiano, L., Rizzone, M., Bergamasco, B., Tavella, A., Torre, E., Perozzo, P. and Lanotte, M.
Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes (195) 167
Lousberg, R., see Rasquin, S.M.C. (203–204) 115
Lu, M., see Chen, J. (199) 17
Ludolph, A.C., see Meyer, T. (199) 85
Luettmann, R.J., see Ellger, T. (205) 35
Lukosava, M., see Wagner, S. (202) 75
Lum, S.Y., see Tan, E.K. (196) 33
Lunetta, C., see Militello, A. (195) 67

Madenci, E., see Bayazıt, Y.A. (196) 77
Madureira, S., see Ferro, J.M. (203–204) 221
Maeda, Y., see Ming, X. (197) 9
Maiorana, G., see Militello, A. (195) 67
Malloy, P., see Salloway, S. (203–204) 227
Mammarella, A., Ferroni, P., Paradiso, M., Martini, F., Paoletti, V., Morino, S., Antonini, G., Gazzaniga, P.P., Musca, A. and Basili, S.
Tumor necrosis factor-alpha and myocardial function in patients with myotonic dystrophy type 1 (201) 59
Manzanilla, B.M., see Yu, R.F. (199) 49
Marie, C., see Demougeot, C. (199) 73
Markowitz, C., see Jeffery, D. (201) 89
Marøy, T.H., see Myhr, K.-M. (202) 93
Marschoff, E.R., see Domínguez, R.O. (203–204) 67
Martin, R., see Chen, M. (201) 71
Martin, W.R.W., see Hanstock, C.C. (198) 37
Martinelli, V., see Rovaris, M. (195) 103
Martini, F., see Mammarella, A. (201) 59
Martini, G., see Borroni, B. (203–204) 189
Martinus, I., see Modi, G. (202) 29

Marui, W., Iseki, E., Nakai, T., Miura, S., Kato, M., Uéda, K. and Kosaka, K.
Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies (195) 153
Marui, W., see Iseki, E. (195) 85
Maruyama, Y., see Tanaka, M. (201) 9
Mashiach, T., see Aharon-Peretz, J. (203–204) 53
Matsuhashi, M., see Ikeda, A. (202) 43
Matsui, M., see Kawachi, T. (199) 79
Matsui, M., see Sakamoto, S. (200) 27
Matsukawa, N., see Akatsu, H. (196) 63
Matsukura, S., see Ohi, T. (197) 73
Matsumoto, R., see Ikeda, A. (202) 43
Matsumura, A., see Nanri, K. (198) 93
Matsuoka, Y., see Konagaya, M. (195) 123
Mattioli, F., Capra, R., Rovaris, M., Chiari, S., Codella, M., Miozzo, A., Gregorini, G. and Filippi, M.
Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides (195) 161
May, A., see Blersch, W. (205) 59
Mayo, D., see Garcia Ruiz, P.J. (202) 59
Mayzel-Oreg, O., see Assaf, Y. (203–204) 235
McDonnell, G.V. and Hawkins, S.A.
Primary progressive multiple sclerosis: increasing clarity but many unanswered questions (199) 1
Mechtler, L.L., see Dubey, N. (205) 77
Meggouh, F., see Benomar, A. (198) 25
Mendel, T., see Członkowska, A. (202) 53
Menken, M.
Neurologic care and the care provided by neurologists: Implications of the World Federation of Neurology workforce survey (198) 1
Metallinos, I.C., see Polychronopoulos, P. (195) 117
Metoki, N., see Sato, Y. (202) 65
Meyer, J.S., Xu, G., Thornby, J., Chowdhury, M. and Quach, M.
Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging (201) 19
Meyer, T., Ludolph, A.C. and Münch, C.
Ifosfamide encephalopathy presenting with asterixis (199) 85
Miao, J., see Geroldi, C. (203–204) 241
Mignini, F., see Amenta, F. (203–204) 147
Mikami, T., Takahashi, T., Ishida, A., Minamiya, Y., Ida, H. and Takada, G.
Signaling pathway for radiation-induced apoptosis in the lymphoblasts from neuronopathic (type A) and non-neuronopathic (type B) forms of Niemann–Pick disease (199) 39
Miki, T., see Tsutada, T. (198) 51
Mikuni, N., see Ikeda, A. (202) 43
Milà, M., see Muñoz, E. (200) 19
Miletich, R.S., see Dubey, N. (205) 77
Militello, A., Vitello, G., Lunetta, C., Toscano, A., Maiorana, G., Piccoli, T. and La Bella, V.
The serum level of free testosterone is reduced in amyotrophic lateral sclerosis (195) 67
Milo, R., see Klein, C. (200) 63
Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M. and Eisdorfer, C.
The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis (202) 13
Minamiya, Y., see Mikami, T. (199) 39
Minc, S., see Lojkowska, W. (203–204) 215
Minematsu, K., see Fujimoto, S. (205) 21
Ming, X., Li, W., Maeda, Y., Blumberg, B., Raval, S., Cook, S.D. and Dowling, P.C.
Caspase-1 expression in multiple sclerosis plaques and cultured glial cells (197) 9
Minohara, M., see Ochi, H. (201) 45
Miozzo, A., see Mattioli, F. (195) 161
Mishra, V.N., see Kalita, J. (198) 21
Misra, U.K., see Kalita, J. (198) 21
Misu, K., see Watanabe, H. (195) 63
Mitsumoto, H., see Naini, A. (198) 17
Mitsuyama, H., see Okamoto, Y. (195) 71
Miura, S., see Marui, W. (195) 153
Miyamoto, S., see Ikeda, A. (202) 43
Mizusawa, H., see Owada, K. (197) 79
Mizutani, T., see Isozaki, E. (197) 37
Modi, G., Modi, M., Martinus, I. and Vangu, M.
New onset seizures in HIV-infected patients without intracranial mass lesions or meningitis—a clinical, radiological and SPECT scan study (202) 29
Modi, M., see Modi, G. (202) 29
Momose, T., see Yoshimura, M. (197) 89
Montagne, C., see De Seze, J. (197) 57
Moody, D.M., see Brown, W.R. (203–204) 159
Moody, D.M., see Challa, V.R. (203–204) 165
Moody, D.M., see Brown, W.R. (203–204) 169
Moran, A.P., Prendergast, M.M. and Hogan, E.L.
Sialosyl-galactose: a common denominator of Guillain–Barré and related disorders? (196) 1
Mordohovitch, M., see Assaf, Y. (203–204) 235
Moretti, R., Torre, P., Antonello, R.M., Cazzato, G. and Bava, A.
Rivastigmine in subcortical vascular dementia: An open 22-month study (203–204) 141
Morgan, P.S., see Vaithianathar, L. (197) 45
Mori, E., see Hosaka, K. (199) 67
Mori, E., see Sakamoto, S. (200) 27
Mori, M., Adachi, Y., Mori, N., Kurihara, S., Kashiwaya, Y., Kusumi, M., Takeshima, T. and Nakashima, K.
Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration (195) 149
Mori, M., Kuwabara, S., Yoshiyama, M., Kanesaka, T., Ogata, T. and Hattori, T.
Successful immune treatment for non-paraneoplastic limbic encephalitis (201) 85
Mori, M., see Kuwabara, S. (199) 89
Mori, M., see Onodera, M. (205) 83
Mori, N., see Mori, M. (195) 149
Mori, T., see Hosaka, K. (199) 67
Mori, T., see Kawachi, T. (199) 79
Mori, T., see Sakamoto, S. (200) 27
Morino, S., see Mammarella, A. (201) 59
Morita, T., see Wada, M. (200) 67
Motizuki, H., see Tanaka, M. (201) 9
Mounier-Vehier, F., see De Seze, J. (197) 57
Münch, C., see Meyer, T. (199) 85
Muñoz, E., Rey, M.J., Milà, M., Cardozo, A., Ribalta, T., Tolosa, E. and Ferrer, I.
Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado–Joseph disease (200) 19
Munsat, T., see Birbeck, G.L. (200) 75
Murai, H., see Ochi, H. (201) 45
Murakami, Y., Furukawa, S., Nitta, A. and Furukawa, Y.
Accumulation of nerve growth factor protein at both rostral and caudal stumps in the transected rat spinal cord (198) 63
Murata, K.-y., Sugie, K., Takamure, M. and Ueno, S.
Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma–polymyositis overlap syndrome (205) 65
Murayama, S., see Saito, Y. (196) 71
Murrell, J.R., see Adamec, E. (200) 85
Musca, A., see Mammarella, A. (201) 59
Musumeci, O., see Naini, A. (198) 17

Mutoh, T., see Hamano, T. (199) 45
Myhr, K.-M., Vågnes, K.S., Marøy, T.H., Aarseth, J.H., Nyland, H.I. and Vedeler, C.A.
Interleukin-10 promoter polymorphisms in patients with multiple sclerosis (202) 93

Nabesima, K., see Ohi, T. (197) 73
Nabesima, K., see Ohi, T. (201) 93
Nadeau, S.E., see Okun, M.S. (201) 79
Nagy, Z., see Vas, Á. (203–204) 259
Naini, A., Musumeci, O., Hayes, L., Pallotti, F., Del Bene, M. and Mitsumoto, H.
Identification of a novel mutation in Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis (198) 17
Naito, E., Ito, M., Yokota, I., Saijo, T., Ogawa, Y. and Kuroda, Y.
Diagnosis and molecular analysis of three male patients with thiamine-responsive pyruvate dehydrogenase complex deficiency (201) 33
Naito, R., see Isozaki, E. (197) 37
Nakagawa, M., see Okamoto, Y. (195) 71
Nakagawa, M., see Ohkubo, R. (198) 31
Nakagawa, M., see Taniwaki, T. (200) 79
Nakai, T., see Marui, W. (195) 153
Nakamura, T., see Fujimoto, T. (196) 21
Nakano, I., see Ishihara, K. (198) 97
Nakao, A., see Watanabe, H. (195) 63
Nakashima, K., see Mori, M. (195) 149
Nakata, M., see Kuwabara, S. (199) 89
Nakayama, T., see Ohi, T. (197) 73
Nakayama, T., see Ohi, T. (201) 93
Nakazawa, H., see Akatsu, H. (196) 63
Namıduru, M., see Yılmaz, M. (197) 69
Nanri, K., Utsumi, H., Yamada, M., Takata, Y., Matsumura, A., Kougo, K., Sekine, S., Ogawa, D. and Toyoda, M.
Transthyretin Val 107 in a Japanese patient with familial amyloid polyneuropathy (198) 93
Nash, N.R., see Glass, J.D. (196) 9
Nelissen, I., Dubois, B., Goris, A., Ronsse, I., Carton, H. and Opdenakker, G.
Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis (200) 43
Nemoto, K., see Kato, N. (202) 69
Neufeld, M.Y., see Chapman, J. (203–204) 81
Neundörfer, B., see Duëctsch, M. (195) 77
Neundörfer, B., see Hecht, M.J. (199) 59
Nicolas, G., see Fressinaud, C. (196) 53
Nicoletti, A., see Le Pira, F. (201) 53
Niewada, M., see Członkowska, A. (202) 53
Niino, M., see Kikuchi, S. (205) 47
Nikoskelainen, E., see Puomila, A. (205) 41
Nishiura, Y., see Fujimoto, T. (196) 21
Nissato, S., see Yoshizawa, T. (195) 129
Nitta, A., see Murakami, Y. (198) 63
Nixon, R.A., see Adamec, E. (200) 85
Nonaka, A., see Ishihara, K. (198) 97
Nyland, H.I., see Myhr, K.-M. (202) 93

O'Brien, J. and Lilienfeld, S.
Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease (203–204) 41
Ochi, H., Osoegawa, M., Wu, X.-M., Minohara, M., Horiuchi, I., Murai, H., Furuya, H. and Kira, J.-i.
Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase (201) 45
Ofovwe, E.C., see Ofovwe, G.E. (200) 49
Ofovwe, G.E., Ibadin, O.M., Ofovwe, E.C. and Okolo, A.A.
Home management of febrile convulsion in an African population: a comparison of urban and rural mothers' knowledge attitude and practice (200) 49
Ogata, T., see Mori, M. (201) 85
Ogawa, D., see Nanri, K. (198) 93
Ogawa, Y., see Naito, E. (201) 33
Oger, J., see Katzberg, H.D. (202) 77
Oh, S.-H., Lee, K.-Y., Im, J.-H. and Lee, M.-S.
Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study a meta-analysis of 53 cases including four present cases (200) 57
Ohara, S., see Ikeda, A. (202) 43
Ohi, T., Saita, K., Takechi, S., Nabesima, K., Tashiro, H., Shiomi, K., Sugimoto, S., Akematsu, T., Nakayama, T., Iwaki, T. and (Japan), S.M.
Corrigendum to "Clinical features and neuropathological findings of familial amyotrophic lateral sclerosis with a His46Arg mutation in Cu/Zn superoxide dismutase" [J. Neurol. Sci. 197 (2002) 73–78] (201) 93
Ohi, T., Saita, K., Takechi, S., Nabesima, K., Tashiro, H., Shiomi, K., Sugimoto, S., Akematsu, T., Nakayama, T., Iwaki, T. and Matsukura, S.
Clinical features and neuropathological findings of familial amyotrophic lateral sclerosis with a His46Arg mutation in Cu/Zn superoxide dismutase (197) 73
Ohkubo, R., Nakagawa, M., Ikeda, K.-i., Kodama, T., Arimura, K., Akiba, S., Saito, M., Ookatsu, Y., Atsuchi, Y., Yamano, Y. and Osame, M.
Cerebrovascular disorders and genetic polymorphisms: mitochondrial DNA5178C is predominant in cerebrovascular disorders (198) 31
Ohlandt, G., see Tyor, W.R. (200) 33
Ohyagi, Y., see Taniwaki, T. (200) 79
Okada, H., see Akatsu, H. (196) 63
Okamoto, Y., Mitsuyama, H., Jonosono, M., Hirata, K., Arimura, K., Osame, M. and Nakagawa, M.
Autosomal dominant palatal myoclonus and spinal cord atrophy (195) 71
Okolo, A.A., see Ofovwe, G.E. (200) 49
Okun, M.S., Nadeau, S.E., Rossi, F. and Triggs, W.J.
Immobilization dystonia (201) 79
Olsson, T., see Gonzalez, H. (205) 9
Ono, K., Komai, K. and Yamada, M.
Myoclonic involuntary movement associated with chronic manganese poisoning (199) 93
Onodera, M., Mori, M., Koga, M., Kamitsukasa, I., Fukutake, T., Hattori, T., Yuki, N. and Kuwabara, S.
Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to *Campylobacter jejuni* enteritis (205) 83
Ookatsu, Y., see Ohkubo, R. (198) 31
Opdenakker, G., see Nelissen, I. (200) 43
Oris, M.Y., see Yu, R.F. (199) 49
Osame, M., see Okamoto, Y. (195) 71
Osame, M., see Ohkubo, R. (198) 31
Osoegawa, M., see Ochi, H. (201) 45
Ouazzani, R., see Benomar, A. (198) 25
Owada, K., Uchihara, T., Ishida, K., Mizusawa, H., Watabiki, S. and Tsuchiya, K.
Motor weakness and cerebellar ataxia in Sjögren syndrome—identification of antineuronal antibody: a case report (197) 79
Ownby, R., see Minagar, A. (202) 13
Oyanagi, K., see Wada, M. (200) 67
Özer, E., see Bayazıt, Y.A. (196) 77

Padovani, A., see Borroni, B. (203–204) 189
Pallotti, F., see Naini, A. (198) 17
Palmeri, A., see Restivo, D.A. (198) 87

Panayi, A.E., Spyrou, N.M., Iversen, B.S., White, M.A. and Part, P.
Determination of cadmium and zinc in Alzheimer's brain tissue using Inductively Coupled Plasma Mass Spectrometry (195) 1
Pánczél, G., see Vas, Á. (203–204) 259
Pandey, R.M., see Shukla, G. (199) 55
Pankiewicz, J., see Slowik, A. (196) 27
Pantoni, L., see Sarti, C. (203–204) 263
Paoletti, V., see Mammarella, A. (201) 59
Papageorgiou, C., see Evdokimidis, I. (195) 25
Papapetropoulos, , see Polychronopoulos, P. (195) 117
Paradiso, M., see Mammarella, A. (201) 59
Parano, E., see Barone, R. (195) 171
Parikh, S.M., Diedrich, A., Biaggioni, I. and Robertson, D.
The nature of the autonomic dysfunction in multiple system atrophy (200) 1
Park, J.-K., see Yang, D.-W. (203–204) 199
Park, M., see Cho, B. (203–204) 109
Part, P., see Panayi, A.E. (195) 1
Paschalis, C., see Polychronopoulos, P. (195) 117
Pavone, P., see Barone, R. (195) 171
Percy, E., see Lambert, E. (198) 43
Perozzo, P., see Lopiano, L. (195) 167
Piccoli, T., see Militello, A. (195) 67
Pieri, V., Diederich, N.J., Raman, R. and Goetz, C.G. (205) 87
Pluta, R.
Glial expression of the β-amyloid peptide in cardiac arrest (203–204) 277
Pollak, L., see Flechter, S. (197) 51
Pollak, L., see Klein, C. (200) 63
Polychronopoulos, P., Gioldasis, G., Ellul, J., Metallinos, I.C., Lekka, N.P., Paschalis, C. and Papapetropoulos,
Family history of stroke in stroke types and subtypes (195) 117
Possa, F., see Rovaris, M. (195) 103
Pratt, R.D.
Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia (203–204) 57
Prendergast, M.M., see Moran, A.P. (196) 1
Prometti, P., see Borroni, B. (203–204) 189
Proukakis, C., Hart, P.E., Cornish, A., Warner, T.T. and Crosby, A.H.
Three novel spastin (*SPG4*) mutations in families with autosomal dominant hereditary spastic paraplegia (201) 65
Pruvo, J.-P., see De Seze, J. (197) 57
Przywara, S., see Blersch, W. (205) 59
Puomila, A., Viitanen, T., Savontaus, M.-L., Nikoskelainen, E. and Huoponen, K.
Segregation of the ND4/11778 and the ND1/3460 mutations in four heteroplasmic LHON families (205) 41

Qin, Z., see Chen, D.-H. (196) 91
Quach, M., see Meyer, J.S. (201) 19

Rabbia, F., see Amenta, F. (203–204) 147
Rabey, J.M., see Flechter, S. (197) 51
Rabey, J.M., see Klein, C. (200) 63
Ramaekers, V.Th., see Häusler, M. (195) 111
Raman, R., see Pieri, V. (205) 87
Rammohan, K., see Jeffery, D. (201) 89
Rao, R.
The role of carotid stenosis in vascular cognitive impairment (203–204) 103
Rapisarda, G., see Restivo, D.A. (198) 87
Rasquin, S.M.C., Verhey, F.R.J., Lousberg, R., Winkens, I. and Lodder, J.
Vascular cognitive disorders: Memory, mental speed and cognitive flexibility after stroke (203–204) 115
Rauhut, U., see Duëctsch, M. (195) 77
Raval, S., see Ming, X. (197) 9
Razumovsky, A.Y., see Geocadin, R.G. (205) 29
Reder, T., see Jeffery, D. (201) 89
Reggio, E., see Le Pira, F. (201) 53
Reider-Groswasser, I.I., see Assaf, Y. (203–204) 235
Restivo, D.A., Lanza, S., Saponara, R., Rapisarda, G., Giuffrida, S. and Palmeri, A.
Changes of cortical excitability of human motor cortex in spinocerebellar ataxia type 2. A study with paired transcranial magnetic stimulation (198) 87
Restivo, D.A., see Le Pira, F. (201) 53
Rey, M.J., see Muñoz, E. (200) 19
Ribalta, T., see Muñoz, E. (200) 19
Rieckmann, P., see Kahl, K.G. (200) 53
Rigaud, A.-S., see Traykov, L. (203–204) 177
Ringelstein, E.B., see Ellger, T. (205) 35
Rizzone, M., see Lopiano, L. (195) 167
Robertson, D., see Parikh, S.M. (200) 1
Rockwood, K.
Vascular cognitive impairment and vascular dementia (203–204) 23
Rodo, M., see Ryglewicz, D. (203–204) 195
Román, G.C.
Vascular dementia may be the most common form of dementia in the elderly (203–204) 7
Romanelli, G., see Borroni, B. (203–204) 189
Ronsse, I., see Nelissen, I. (200) 43
Ronzoni, M., see Scarpini, E. (195) 41
Roose, S., see Salloway, S. (203–204) 227
Ropele, S., see Schmidt, R. (203–204) 253
Rosenberg, C., see Salloway, S. (203–204) 183
Rosmarin, A.G., see Gyrd-Hansen, M. (197) 27
Rossi, F., see Okun, M.S. (201) 79
Röther, J., see Terborg, C. (205) 15
Rouaud, O., see Demougeot, C. (199) 73
Rovaris, M., Iannucci, G., Falautano, M., Possa, F., Martinelli, V., Comi, G. and Filippi, M.
Cognitive dysfunction in patients with mildly disabling relapsing–remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging (195) 103
Rovaris, M., see Mattioli, F. (195) 161
Rozzini, L., see Borroni, B. (203–204) 189
Russell, D.
Cerebral microemboli and cognitive impairment (203–204) 211
Ruutiainen, J., see Seinelä, A. (198) 79
Ryglewicz, D., Rodo, M., Kunicki, P.K., Bednarska-Makaruk, M., Graban, A., Lojkowska, W. and Wehr, H.
Plasma antioxidant activity and vascular dementia (203–204) 195
Ryglewicz, D., see Członkowska, A. (202) 53
Ryglewicz, D., see Lojkowska, W. (203–204) 215

Sackheim, H., see Salloway, S. (203–204) 227
Saijo, T., see Naito, E. (201) 33
Saita, K., see Ohi, T. (197) 73
Saita, K., see Ohi, T. (201) 93
Saito, M., see Ohkubo, R. (198) 31
Saito, Y., Yamazaki, M., Kanazawa, I. and Murayama, S.
Severe involvement of the ambient gyrus in a case of dementia with argyrophilic grain disease (196) 71
Sakai, M., see Konagaya, M. (195) 123
Sakamoto, S., Ishii, K., Sasaki, M., Hosaka, K., Mori, T., Matsui, M., Hirono, N. and Mori, E.
Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease (200) 27
Sakamoto, S., see Hosaka, K. (199) 67
Sakamoto, S., see Kawachi, T. (199) 79
Saleh El-Baroni, I., see Członkowska, A. (202) 53

Salloway, S., Correia, S., Boyle, P., Malloy, P., Schneider, L., Lavretsky, H., Sackheim, H., Roose, S. and Krishnan, K.R.R.
MRI subcortical hyperintensities in old and very old depressed outpatients: The important role of age in late-life depression (203–204) 227
Salloway, S., Gur, T., Berzin, T., Zipser, B., Correia, S., Hovanesian, V., Fallon, J., Kuo-Leblanc, V., Glass, D., Hulette, C., Rosenberg, C., Vitek, M. and Stopa, E.
Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease (203–204) 183
Sandercock, P., see Członkowska, A. (202) 53
San Jose, Ma.C.Z., see Yu, R.F. (199) 49
Saponara, R., see Restivo, D.A. (198) 87
Saponara, R., see Le Pira, F. (201) 53
Sarchielli, P., Alberti, A., Floridi, A. and Gallai, V.
L-Arginine/nitric oxide pathway in chronic tension-type headache: relation with serotonin content and secretion and glutamate content (198) 9
Sarti, C., Pantoni, L., Bartolini, L. and Inzitari, D.
Cognitive impairment and chronic cerebral hypoperfusion: What can be learned from experimental models (203–204) 263
Sasaki, I., see Deguchi, K. (199) 31
Sasaki, M., see Hosaka, K. (199) 67
Sasaki, M., see Kawachi, T. (199) 79
Sasaki, M., see Sakamoto, S. (200) 27
Sasaki, M., see Taniwaki, T. (200) 79
Sato, T., see Akatsu, H. (196) 63
Sato, T., see Ikeda, A. (202) 43
Sato, Y., Kaji, M., Kondo, I., Yoshida, H., Satoh, K. and Metoki, N.
Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: Effect of combined therapy with folic acid and mecobalamine (202) 65
Satoh, K., see Sato, Y. (202) 65
Saurugg, R., see Schmidt, R. (203–204) 253
Savontaus, M.-L., see Puomila, A. (205) 41
Scarlato, G., see Conti, G. (195) 35
Scarlato, G., see Scarpini, E. (195) 41
Scarlato, G., see Del Bo, R. (202) 85
Scarpini, E., Galimberti, D., Baron, P., Clerici, R., Ronzoni, M., Conti, G. and Scarlato, G.
IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease (195) 41
Scarpini, E.
A tribute to Guglielmo Scarlato, MD (1931–2002) (205) 3
Scarpini, E., see Conti, G. (195) 35
Schaade, L., see Häusler, M. (195) 111
Schack, B., see Terborg, C. (205) 71
Schmidt, H., see Schmidt, R. (203–204) 253
Schmidt, R., Schmidt, H., Kapeller, P., Enzinger, C., Ropele, S., Saurugg, R. and Fazekas, F.
The natural course of MRI white matter hyperintensities (203–204) 253
Schmidtke, K. and Hüll, M.
Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia (203–204) 17
Schmitt, M., see Benomar, A. (198) 25
Schmitz, P.I.M., see Bernsen, R.A.J.A.M. (201) 13
Schneider, L., see Salloway, S. (203–204) 227
Schoenmackers, C., see Häusler, M. (195) 111
Schulte-Mattler, W.J., see Blersch, W. (205) 59
Schwaninger, M., see Wagner, S. (202) 75
Schwartzman, R.J., see Hansrote, S. (197) 63
Schweizer, K., see Häusler, M. (195) 111
Sciacco, M., see Del Bo, R. (202) 85
Seinelä, A., Hämäläinen, P., Koivisto, M. and Ruutiainen, J.
Conscious and unconscious uses of memory in multiple sclerosis (198) 79
Sekine, S., see Nanri, K. (198) 93
Selak, M., see Hansrote, S. (197) 63
Serra, J.A., see Domínguez, R.O. (203–204) 67
Shapshak, P., see Minagar, A. (202) 13
Sharief, M., see Jeffery, D. (201) 89
Shen, C.-C., see Wang, Y.-C. (202) 35
Shibasaki, H., see Ikeda, A. (202) 43
Shigematsu, J., see Yasuda, T. (197) 19
Shimada, H., see Tsutada, T. (198) 51
Shimogawara, M., see Tsutada, T. (198) 51
Shiomi, K., see Ohi, T. (197) 73
Shiomi, K., see Ohi, T. (201) 93
Shiota, J.-i., see Ishihara, K. (198) 97
Shirabe, S., see Fujimoto, T. (196) 21
Shirouzu, I., see Yoshimura, M. (197) 89
Shoji, S., see Yoshizawa, T. (195) 129
Shukla, G., Bhatia, M., Pandey, R.M. and Behari, M.
Peripheral silent periods in essential tremor (199) 55
Siciliano, G., see Alaedini, A. (196) 41
Sienkiewicz-Jarosz, H., see Lojkowska, W. (203–204) 215
Singhal, A.B., Topcuoglu, M.A. and Koroshetz, W.J.
Diffusion MRI in three types of anoxic encephalopathy (196) 37
Sinha, K., see Gupta, Y.K. (203–204) 267
Sinigaglia-Coimbra, R., Cavalheiro, E.A. and Coimbra, C.
Protective effect of systemic treatment with cyclosporine A after global ischemia in rats (203–204) 273
Slowik, A., Turaj, W., Pankiewicz, J., Dziedzic, T., Szermer, P. and Szczudlik, A.
Hypercortisolemia in acute stroke is related to the inflammatory response (196) 27
Smagghe, A., see Traykov, L. (203–204) 177
Smyrnis, N., see Evdokimidis, I. (195) 25
Sng, E.C.S., see Auchus, A.P. (203–204) 85
Sobue, G., see Watanabe, H. (195) 63
Sodagar, S.N., see Auchus, A.P. (203–204) 85
Sohn, H.-S., see Yang, D.-W. (203–204) 199
Solomon, J., see Duëctsch, M. (195) 77
Spyrou, N.M., see Panayi, A.E. (195) 1
Srivastava, R.A.K. and Jain, J.C.
Scavenger receptor class B type I expression and elemental analysis in cerebellum and parietal cortex regions of the Alzheimer's disease brain (196) 45
Stål, P.S., see Lindman, R. (195) 11
Stassen, M.H.W., see De Baets, M. (202) 5
Stemper, B., see Hilz, M.J. (196) 81
Stojkovic, T., see De Seze, J. (197) 57
Stopa, E., see Salloway, S. (203–204) 183
Sugie, K., see Murata, K.-y. (205) 65
Sugie, M., see Tanaka, M. (201) 9
Sugimoto, S., see Ohi, T. (197) 73
Sugimoto, S., see Ohi, T. (201) 93
Sung, J.-Y., see Kuwabara, S. (199) 89
Susuki, K., Yuki, N., Hirata, K. and Kuwabara, S.
Fine specificities of anti-LM1 IgG antibodies in Guillain–Barré syndrome (195) 145
Szabó, Z., see Vas, Á. (203–204) 259
Szatmári, S., Csiba, L., Fekete, I. and Bereczki, D.
Subcortical features and cognitive performance in Hungarian cerebrovascular outpatients (203–204) 99
Szczudlik, A., see Slowik, A. (196) 27
Sze, C.-I., see Bi, H. (200) 11
Szermer, P., see Slowik, A. (196) 27
Szirmai, I., Vastagh, I., Szombathelyi, É. and Kamondi, A.
Strategic infarcts of the thalamus in vascular dementia (203–204) 91
Szombathelyi, É., see Szirmai, I. (203–204) 91

Tagaya, M., see Fujimoto, S. (205) 21
Takada, G., see Mikami, T. (199) 39

Takahashi, J., see Ikeda, A. (202) 43
Takahashi, M., see Akatsu, H. (196) 63
Takahashi, S., see Yasuda, T. (197) 19
Takahashi, T., see Mikami, T. (199) 39
Takamure, M., see Murata, K.-y. (205) 65
Takao, M., see Adamec, E. (200) 85
Takata, Y., see Nanri, K. (198) 93
Takayama, M., see Ikeda, A. (202) 43
Takayama, N., see Iseki, E. (195) 85
Takechi, S., see Ohi, T. (197) 73
Takechi, S., see Ohi, T. (201) 93
Takeshima, T., see Mori, M. (195) 149
Takeuchi, H., see Deguchi, K. (199) 31
Taki, W., see Ikeda, A. (202) 43
Tan, E.K., Lum, S.Y. and Wong, M.C.
Restless legs syndrome in Parkinson's disease (196) 33
Tanaka, K., see Tanaka, M. (201) 9
Tanaka, M., Maruyama, Y., Sugie, M., Motizuki, H., Kamakura, K. and Tanaka, K.
Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome (201) 9
Taniwaki, T., Nakagawa, M., Yamada, T., Yoshida, T., Ohyagi, Y., Sasaki, M., Kuwabara, Y., Tobimatsu, S. and Kira, J.-i.
Cerebral metabolic changes in early multiple system atrophy: a PET study (200) 79
Tarakcıoğlu, M., see Yılmaz, M. (197) 69
Tashiro, H., see Ohi, T. (197) 73
Tashiro, H., see Ohi, T. (201) 93
Tashiro, K., see Kikuchi, S. (205) 47
Tavella, A., see Lopiano, L. (195) 167
Tench, C.R., see Vaithianathar, L. (197) 45
Terborg, C., Birkner, T., Schack, B. and Witte, O.W.
Acute effects of cigarette smoking on cerebral oxygenation and hemodynamics: A combined study with near-infrared spectroscopy and transcranial Doppler sonography (205) 71
Terborg, C., Bramer, S., Weiller, C. and Röther, J.
Short-term effect of cigarette smoking on CO_2-induced vasomotor reactivity in man: A study with near-infrared spectroscopy and tanscranial Doppler sonography (205) 15
Testa, C., see Geroldi, C. (203–204) 241
Tham, W., Auchus, A.P., Thong, M., Goh, M.-L., Chang, H.-M., Wong, M.-C. and Chen, C.P.L.-H.
Progression of cognitive impairment after stroke: One year results from a longitudinal study of Singaporean stroke patients (203–204) 49
Thong, M., see Tham, W. (203–204) 49
Thong, M., see Auchus, A.P. (203–204) 85
Thore, C.R., see Brown, W.R. (203–204) 159
Thore, C.R., see Challa, V.R. (203–204) 165
Thore, C.R., see Brown, W.R. (203–204) 169
Thornby, J., see Meyer, J.S. (201) 19
Thyagarajan, D., see Lewis, S. (201) 39
Tiriticco, M., see Conti, G. (195) 35
Tobimatsu, S., see Yasuda, T. (197) 19
Tobimatsu, S., see Taniwaki, T. (200) 79
Tolosa, E., see Muñoz, E. (200) 19
Tomassoni, D., see Amenta, F. (203–204) 147
Tomer, R., see Aharon-Peretz, J. (203–204) 53
Toole, J.F.
Professor Dr. George W. Bruyn (1928–2002) (205) 1
Toole, J.F.
Vitamin intervention for stroke prevention (203–204) 121
Topcuoglu, M.A., see Singhal, A.B. (196) 37
Torre, E., see Lopiano, L. (195) 167
Torre, P., see Moretti, R. (203–204) 141
Toscano, A., see Militello, A. (195) 67
Touge, T., see Deguchi, K. (199) 31
Toyka, K.V., see Kahl, K.G. (200) 53
Toyoda, M., see Nanri, K. (198) 93
Traon, A.P.-L., Costes-Salon, M.-C., Galinier, M., Fourcade, J. and (France), V.L.
Corrigendum to "Dynamics of cerebral blood flow autoregulation in hypertensive patients" [J. Neurol. Sci. 195 (2002) 139–144] (201) 91
Traon, A.P.-L., Costes-Salon, M.-C., Galinier, M., Fourcade, J. and Larrue, V.
Dynamics of cerebral blood flow autoregulation in hypertensive patients (195) 139
Traykov, L., Rigaud, A.-S., Baudic, S., Smagghe, A., Boller, F. and Forette, F.
Apolipoprotein E $\varepsilon 4$ allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease (203–204) 177
Trenkwalder, C., see Baier, P.C. (198) 71
Treves, T.A., see Chapman, J. (203–204) 81
Trifiletti, R.R., see Barone, R. (195) 171
Triggs, W.J., see Okun, M.S. (201) 79
Tsuchiya, K., see Owada, K. (197) 79
Tsukaguchi, M., see Deguchi, K. (199) 31
Tsutada, T., Ikeda, H., Tsuyuguchi, N., Hattori, H., Shimogawara, M., Shimada, H. and Miki, T.
Detecting functional asymmetries through the dipole moment of magnetoencephalography (198) 51
Tsuyuguchi, N., see Tsutada, T. (198) 51
Turaj, W., see Slowik, A. (196) 27
Tyor, W.R., Avgeropoulos, N., Ohlandt, G. and Hogan, E.L.
Treatment of spinal cord impact injury in the rat with transforming growth factor-β (200) 33

Uchihara, T., see Owada, K. (197) 79
Uéda, K., see Iseki, E. (195) 85
Uéda, K., see Marui, W. (195) 153
Ueno, S., see Murata, K.-y. (205) 65
Ulatowski, J.A., see Geocadin, R.G. (205) 29
(USA), J.W., see Jeffery, D. (201) 89
Utsumi, H., see Nanri, K. (198) 93

Vågnes, K.S., see Myhr, K.-M. (202) 93
Vaithianathar, L., Tench, C.R., Morgan, P.S., Lin, X. and Blumhardt, L.D.
White matter T_1 relaxation time histograms and cerebral atrophy in multiple sclerosis (197) 45
Valdivieso, F., see Frank, A. (203–204) 173
Van der Meché, F.G.A., see Bernsen, R.A.J.A.M. (201) 13
Vangu, M., see Modi, G. (202) 29
Vardi, J., see Flechter, S. (197) 51
Vardinon, N., see Chapman, J. (203–204) 81
Vas, Á., Gulyás, B., Szabó, Z., Bönöczk, P., Csiba, L., Kiss, B., Kárpáti, E., Pánczél, G. and Nagy, Z.
Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: A summary of evidences (203–204) 259
Vastagh, I., see Szirmai, I. (203–204) 91
Vedeler, C., see Conti, G. (195) 35
Vedeler, C.A., see Myhr, K.-M. (202) 93
Veglio, F., see Amenta, F. (203–204) 147
Verchovsky, R., see Assaf, Y. (203–204) 235
Verhey, F.R.J., see Rasquin, S.M.C. (203–204) 115
Verier, A., see De Seze, J. (197) 57
Vermersch, P., see De Seze, J. (197) 57
Vigneron, I., see Fressinaud, C. (196) 53
Viitanen, T., see Puomila, A. (205) 41
Vila, J., see Domínguez, R.O. (203–204) 67

Vitek, M., see Salloway, S. (203–204) 183
Vitello, G., see Militello, A. (195) 67
Vonsattel, J.P., see Adamec, E. (200) 85

Wada, M., Kamata, M., Aizu, Y., Morita, T., Hu, J. and Oyanagi, K.
Alteration of midkine expression in the ischemic brain of humans (200) 67
Wagner, S., Kalb, P., Lukosava, M., Hilgenfeldt, U. and Schwaninger, M.
Activation of the tissue kallikrein–kinin system in stroke (202) 75
Wagnerova, J., Cervenakova, L., Balabanov, R., Zitron, I. and Dore-Duffy, P.
Cytokine regulation of E-selectin in rat CNS microvascular endothelial cells: differential response of CNS and non-CNS vessels (195) 51
Walker, P., see Demougeot, C. (199) 73
Wallström, E., see Gonzalez, H. (205) 9
Wang, L., see Chen, J. (199) 17
Wang, Y.-C., Lin, C.-W., Shen, C.-C., Lai, S.-C. and Kuo, J.-S.
Tissue plasminogen activator for the treatment of intraventricular hematoma: The dose–effect relationship (202) 35
Warner, T.T., see Proukakis, C. (201) 65
Wasay, M., see Dubey, N. (205) 77
Watabiki, S., see Owada, K. (197) 79
Watanabe, H., Misu, K., Kobayashi, T., Hattori, N., Doyu, M., Yokoyama, I., Ando, Y., Nakao, A. and Sobue, G.
ABO-incompatible auxiliary partial orthotopic liver transplant for late-onset familial amyloid polyneuropathy (195) 63
Wehr, H., see Ryglewicz, D. (203–204) 195
Weiller, C., see Terborg, C. (205) 15
White, M.A., see Panayi, A.E. (195) 1
Winkelmann, J., see Baier, P.C. (198) 71
Winkens, I., see Rasquin, S.M.C. (203–204) 115
Wirguin, I., see Alaedini, A. (196) 41
Witte, O.W., see Terborg, C. (205) 71
Wityk, R.J., see Geocadin, R.G. (205) 29
Wohlfarth, K., see Blersch, W. (205) 59
Wong, M.-C., see Tham, W. (203–204) 49
Wong, M.C., see Tan, E.K. (196) 33
World Federation of Neurology Task Force on Neurological Services, see Bergen, D.C. (198) 3
Wu, X.-M., see Ochi, H. (201) 45

Xu, G., see Meyer, J.S. (201) 19

Yabe, I., see Kikuchi, S. (205) 47
Yahyaoui, M., see Benomar, A. (198) 25
Yamada, M., see Nanri, K. (198) 93
Yamada, M., see Ono, K. (199) 93
Yamada, T., see Akatsu, H. (196) 63
Yamada, T., see Taniwaki, T. (200) 79
Yamaguchi, T., see Fujimoto, S. (205) 21
Yamamoto, J., see Ikeda, A. (202) 43
Yamamoto, T., see Akatsu, H. (196) 63
Yamamoto, T., see Yoshimura, M. (197) 89
Yamano, Y., see Ohkubo, R. (198) 31
Yamazaki, M., see Saito, Y. (196) 71
Yang, D.-W., Kim, B.-S., Park, J.-K., Kim, S.-Y., Kim, E.-N. and Sohn, H.-S.
Analysis of cerebral blood flow of subcortical vascular dementia with single photon emission computed tomography: Adaptation of statistical parametric mapping (203–204) 199
Yang, D.W., see Cho, B. (203–204) 109
Yang, J., see Cho, B. (203–204) 109
Yasuda, T., Shigematsu, J., Tobimatsu, S., Takahashi, S. and Kato, M.
Persistent hypertension does not alter the cerebral blood flow and glucose utilization in young-adult Dahl salt-sensitive rats (197) 19
Yılmaz, M., Tarakcıoğlu, M., Bayazıt, N., Bayazıt, Y.A., Namıduru, M. and Kanlıkama, M.
Serum cytokine levels in bell's palsy (197) 69
Yokota, C., see Fujimoto, S. (205) 21
Yokota, I., see Naito, E. (201) 33
Yokoyama, I., see Watanabe, H. (195) 63
Yoshida, H., see Sato, Y. (202) 65
Yoshida, T., see Taniwaki, T. (200) 79
Yoshimura, M., Yamamoto, T., Iso-o, N., Imafuku, I., Momose, T., Shirouzu, I., Kwak, S. and Kanazawa, I.
Hemiparkinsonism associated with a mesencephalic tumor (197) 89
Yoshiyama, M., see Mori, M. (201) 85
Yoshizawa, T., Kohno, Y., Nissato, S. and Shoji, S.
Compound heterozygosity with two novel mutations in the *HEXB* gene produces adult Sandhoff disease presenting as a motor neuron disease phenotype (195) 129
Yu, R.F., San Jose, Ma.C.Z., Manzanilla, B.M., Oris, M.Y. and Gan, R.
Sources and reasons for delays in the care of acute stroke patients (199) 49
Yueh, K.-C., see Lin, J.-J. (199) 25
Yuki, N., see Susuki, K. (195) 145
Yuki, N., see Kuwabara, S. (199) 89
Yuki, N., see Onodera, M. (205) 83
Yust, I., see Chapman, J. (203–204) 81

Zaim, A., see Benomar, A. (198) 25
Zalonis, I., see Evdokimidis, I. (195) 25
Zappalà, G., see Le Pira, F. (201) 53
Zipser, B., see Salloway, S. (203–204) 183
Zis, P.V., see Evdokimidis, I. (195) 25
Zitron, I., see Wagnerova, J. (195) 51
Zumo, L. and Grewal, R.P.
Castleman's disease-associated neuropathy: no evidence of human herpesvirus type 8 infection (195) 47

ELSEVIER

Journal of the Neurological Sciences 205 (2002) 107–112

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

Cumulative Subject Index, Volumes 195–205 (2002)

AAA cassette (201) 65
ABO-incompatible (195) 63
Access (200) 75
ACE (198) 31
Acetazolamide (205) 21
Acetylcholine receptor (202) 5
Acetylcholine receptor antibody (202) 77
Acid sphingomyelinase (199) 39
Acute inflammatory demyelinating polyneuropathy (196) 41
Acute ischemic stroke (202) 25
Acute motor and sensory axonal neuropathy (196) 41
Acute motor axonal neuropathy (196) 41, (199) 89
Acute oropharyngeal palsy (205) 83
Acute polyneuropathy (200) 63
Acute stroke (199) 49
Acyclovir, therapeutic use (195) 111
adPEO (201) 39
Adult-onset Alexander disease (195) 71
Age (200) 27
Ageing (202) 85
Aging (198) 31, (198) 71
Agrin (203–204) 183
Alpha-tocopherol gene (198) 25
ALS (195) 25
Alzheimer disease (201) 19, (202) 13, (203–204) 189
Alzheimer's Disease (195) 1
Alzheimer's disease (200) 27, (203–204) 17 (203–204) 23, (203–204) 29, (203–204) 35, (203–204) 41, (203–204) 73, (203–204) 125, (203–204) 131, (203–204) 137, (203–204) 177, (203–204) 183, (203–204) 207, (203–204) 215, (203–204) 247, (203–204) 277
Alzheimer-type dementia (196) 63
Alzhemier's disease (196) 45
Amyotrophic lateral sclerosis (195) 67, (198) 37, (199) 59
Angiotensin-converting enzyme (199) 25
Anoxia (196) 37
Antibodies (202) 5
Anticoagulation (202) 25
Anti-ganglioside antibodies (196) 1
Anti-ganglioside antibody (195) 145, (199) 89, (205) 83
Antigen-presenting cell (205) 65
Anti-Hu antibody (201) 9
Anti-hypertensive drugs (203–204) 147
Antineural antibody (197) 79
Antioxidant defense (203–204) 195
Antiphospholipid syndrome (203–204) 81
Anti-saccade (195) 25
Aphasia (203–204) 91
Apnea (195) 11
ApoE (203–204) 173
APOE (203–204) 183
Apolipoprotein E (ApoE) (203–204) 177
Apoptosis (195) 35, (203–204) 169, (203–204) 207
Arrhythmia (198) 43
Arteriolar tortuosity (203–204) 159
Arterioles (203–204) 165
Asterixis (199) 85
Astrocyte (200) 67
Astrocytes (202) 13, (203–204) 277
Ataxic hemiparesis (197) 85
Atherosclerosis (203–204) 211
Atrial fibrillation (202) 25, (202) 53
Attitude (200) 49
Australian pedigrees (201) 39
Autoimmune (201) 45
Autoimmune disease (196) 1, (201) 85, (203–204) 81
Autoimmune mechanisms (203–204) 3
Autoimmunity (203–204) 273
Autonomic (200) 1
Autonomic dysfunction (200) 79
Autonomic function (199) 31
Autonomic nervous system (195) 77
Autosomal dominant cerebellar ataxia (201) 53
Autosomal dominant palatal myoclonus (195) 71
Axon (196) 9
Axonal cytoskeleton (196) 53
Axonopathy (196) 53
Axotomy (196) 9

β-amyloid (196) 71
β-Amyloid peptide (203–204) 277
17-βestradiol (195) 67
Barriers to care (200) 75
Basement membrane (203–204) 183
BB-1 (205) 65
BCAA (195) 149
Behavioral test (199) 17
Behaviour (203–204) 141
Bell's palsy (197) 69
Blood glucose (201) 1
Blood pressure (201) 1
Body temperature (201) 1
Bone marrow cell (199) 17
Botulinum neurotoxin (205) 59
Bradykinin (202) 75
Brain (196) 45, (203–204) 165, (205) 77
Brain glucose metabolism (203–204) 259
Brain imaging (203–204) 235
Brain ischemia (203–204) 277
Brain tissue (195) 1
Bulbar palsy (198) 93, (205) 83

CADASIL (203–204) 77
Cadmium (195) 1
CAG (200) 19

PII: S0022-510X(02)00407-0

Calcium (198) 9
Calpain (196) 9
Calpastatin (196) 9
Campylobacter jejuni (196) 1
Cap disease (201) 27
Capillaries (203–204) 165, (203–204) 183
Cardiac arrest (203–204) 277
Cardiac sympathetic denervation (199) 31
Cardiomyopathy (198) 93
Cardiovascular reflex (199) 31
Cardiovascular risk factors (203–204) 227
Carotid stenosis (203–204) 103
Carpal tunnel syndrome (198) 93
Case mix (202) 53
Caspase-1 (197) 9
Castleman's disease (195) 47
Cause of death (202) 53
Cavernous malformation (196) 91
[^{14}C]deoxyglucose method (197) 19
CD40 ligand (196) 21
Celloidin (203–204) 165
Central nervous system (195) 51
Central sensitization (198) 9
Cerebellar ataxia (195) 71, (195) 149, (197) 79, (200) 79
Cerebral atrophy (195) 123, (197) 45
Cerebral autoregulation (195) 139
Cerebral blood flow (197) 19, (198) 51, (202) 35, (203–204) 199, (203–204) 259
Cerebral embolism (203–204) 211
Cerebral hemodynamics (205) 15
Cerebral hypoperfusion (203–204) 263
Cerebral infarct (200) 67
Cerebral ischemia (203–204) 273
Cerebral metabolism (197) 19
Cerebrospinal fluid (195) 41
Cerebrovascular chronic progressive form (203–204) 67
Cerebrovascular disease (203–204) 23, (203–204) 29, (203–204) 41, (203–204) 57, (203–204) 77, (203–204) 115, (203–204) 125, (203–204) 131, (203–204) 137, (203–204) 173, (203–204) 177, (203–204) 241
Cerebrovascular disorders (198) 31, (198) 43
Chemokines (195) 41
Choline (198) 37
Cholinergic synapse (203–204) 131
Cholinesterase inhibition (203–204) 141
Cholinesterase inhibitors (203–204) 57
Chorea (202) 59
Chronic (202) 65
Chronic inflammation (202) 69
Chronic neuronal death (CND) (203–204) 273
Chronic tension-type headache (198) 9
Churg–Strauss syndrome (195) 161
Cigarette smoking (205) 15, (205) 71
Circulating anticoagulant (203–204) 81
Citalopram (203–204) 227
Clinical course (202) 93
Clinical features (197) 73, (203–204) 57
Clinical outcomes (203–204) 41
Clinical studies (203–204) 259
Clinical trials (203–204) 57, (203–204) 147
Clinical variations (201) 39
Cognition (203–204) 115, (203–204) 147, (203–204) 221, (203–204) 253, (203–204) 267
Cognitive disorders (201) 19
Cognitive evaluation (203–204) 263
Cognitive impairment (195) 103, (195) 161, (201) 53, (203–204) 49, (203–204) 103, (203–204) 211
Cognitive processing (205) 35
Cognitive screening (201) 19
Cold pressor test (196) 81
Collagen (203–204) 165
Coma (196) 37
Common carotid artery ligation (203–204) 263
Complete infarcts (203–204) 67
Compound heterozygosity (195) 129
Computerization (203–204) 109
Confocal microscopy (200) 85
Congenital myopathy (201) 27
^{11}C-NMSP positron emission tomography (197) 89
Conscious level (202) 53
Copaxone® (201) 71
Cortical excitability (198) 87
Cortical silent period (198) 87
Corticobasal degeneration (199) 67
Cortisol (196) 27
Costimulatory molecule (205) 65
CPEO (197) 63
Creatine (198) 37
Criteria (203–204) 11
Cross-sectional study (205) 35
Crush injury (202) 69
CSF (197) 57, (205) 9
Cultures (197) 9
Cyclic guanosine 3′,5′ monophosphate—cGMP (198) 9
Cyclosporine A (203–204) 273
Cytokines (195) 51, (197) 69, (200) 33, (201) 1, (201) 59, (205) 9
Cytotoxic T cells (201) 9

Dahl rats (197) 19
Deep brain stimulation (195) 167
Dehydroepiandrosterone sulphate (195) 67
Delayed neuronal death (DND) (203–204) 273
Dementia (203–204) 17, (203–204) 49, (203–204) 53, (203–204) 77, (203–204) 81, (203–204) 85, (203–204) 91, (203–204) 109, (203–204) 199, (203–204) 215, (203–204) 221, (203–204) 241
Dementia, vascular (201) 19
Dementia with Lewy bodies (195) 85, (195) 153, (196) 63
Depression (205) 51
Deterioration (201) 1
Developing country (200) 75
Devic's syndrome (197) 57
Diagnosis (201) 19, (203–204) 3, (203–204) 215
Diagnostic criteria (203–204) 23
Diastolic function (201) 59
Diffuse plaque (196) 71
Diffusion (203–204) 235
Diffusion tensor MRI (195) 103
Diffusion-weighted imaging (196) 37, (203–204) 235
Dipole moment (198) 51
Disability (195) 103, (202) 93, (205) 51
Disease susceptibility (202) 93
Dizziness (196) 77
L-DOPA (197) 89
Dopamine (200) 79
Duchenne muscular dystrophy (197) 27
Dysphonia (198) 93
Dystonia (201) 79, (202) 59

Early case fatality (202) 53
Early diagnosis (203–204) 247
E1α subunit (201) 33
Edema (202) 35, (202) 75
EDSS (205) 35

EEG (198) 21
Elderly (203–204) 7
Electrical (199) 55
Elemental analysis (196) 45
EMG (199) 45
Encephalitis, viral (195) 111
Encephalopathy (199) 85
Endothelial cells (195) 51
Endothelial dysfunction (203–204) 189
Enzyme immunoassay (EIA) (198) 63
Epidemiology (203–204) 73
Epilepsy (196) 91, (202) 43
Epileptogenic zone (202) 43
E-selectin (195) 51
Essential tremor (199) 55
Event-related potentials (205) 35
Evoked potential (198) 21
Excitotoxicity (200) 11
Executive function (203–204) 141
Expanded disability status scale (205) 51
Experimental diabetic neuropathy (195) 35
Experimental models (203–204) 263

Failure in maturation (201) 27
FALS with His46Arg mutation (197) 73
Familial amyloid polyneuropathy (195) 63, (198) 93
Familial amyotrophic lateral sclerosis (198) 17
Family history of stroke (195) 117
Fatigue (205) 51
Fatigue severity scale (205) 51
FDG (199) 79
^{18}F-DOPA positron emission tomography (197) 89
Febrile convulsion (200) 49
Ferritin (201) 1
Fibre types (195) 11
Fibromyalgia syndrome (196) 77
Fine specificity (195) 145
Fluid attenuated inversion recovery (FLAIR) (199) 59
Fluorodeoxyglucose (FDG) (203–204) 247
Folic acid (203–204) 121
Follow-up (197) 51
Follow-up examination (199) 59
Formation process (195) 85
Friedreich ataxia (198) 25
Frontal lobe (195) 25, (195) 123, (203–204) 103
Frontotemporal dementia (200) 85, (203–204) 215
Functional asymmetries (198) 51
Functional imaging (203–204) 247

GAA expansion (198) 25
GABP (197) 27
Galantamine (203–204) 29, (203–204) 125, (203–204) 131
GAL-INT-6 study (203–204) 125
Ganglioside antibodies (196) 41
Gelatinase B (200) 43
Gender (199) 79
Gene regulation (195) 51
Genetic polymorphism (199) 25
Genetics (196) 91, (199) 1, (205) 47
Genetic susceptibility (199) 25
Geriatric depression (203–204) 227
GFAP (195) 71
G_{M2} gangliosidoses (195) 129
Glatiramer acetate (197) 51, (201) 71
Glial cytoplasmic inclusion (195) 123
Glial fibrillary acidic protein (200) 67
Global cerebral ischemia (196) 37
Glucose metabolism (199) 67, (199) 79, (200) 27, (200) 79
Glutamate (198) 9, (200) 11
GT1a (205) 83
Guillain-Barré syndrome (196) 41
Guillain–Barré syndrome (195) 145, (196) 1, (199) 89, (201) 13, (205) 83

HAM/*TSP* (196) 21
HAM/TSP (201) 45
Haploinsufficiency (201) 65
Hearing loss (196) 77
Heart surgery (203–204) 211
Hemichorea (200) 57
Hemodynamics (205) 21
Hemostasis changes (203–204) 189
Heparin (202) 25
Hereditary ataxias (202) 59
Hereditary sensory and autonomic neuropathy (196) 81
Hereditary spastic paraplegia (201) 65
Heteroplasmy (205) 41
Hippocampus (195) 85
HIV-associated dementia (202) 13
HIV infection (202) 29
HLA supertype (201) 9
Home (200) 49
Homocysteine (202) 65
H-reflex (199) 89
HTLV-1-associated myelopathy (199) 45
HTLV-I (196) 21
Human (200) 67
Human herpesvirus type 8 (HHV-8) (195) 47
Hydrogen clearance method (197) 19
Hyperglycemia (200) 57
Hyperintensity basal ganglia lesion (200) 57
Hyperreflexia (199) 89
Hypertension (195) 139, (197) 19, (203–204) 147
Hypothalamus (199) 79

Ifosfamide (199) 85
IL-1β (195) 35
IL-5 (201) 45
IL-10 promoter polymorphism (202) 93
IL-12 (196) 21
IL-12 receptor (196) 21
IL-13 (201) 45
Illiteracy (203–204) 73
Imaging (203–204) 11
Immobilization (201) 79
Immune deviation (201) 71
Immunohistochemistry (195) 153, (198) 63, (200) 85
Immunology (199) 1
Immunomodulatory agents (197) 1
Immunotherapy (201) 71
Incidence (203–204) 153
Incomplete white matter lesions (203–204) 67
Inductively Coupled Plasma Mass Spectrometry (195) 1
Infarct (203–204) 91
Inflammation (195) 41, (205) 9, (205) 77
Inflammatory response (196) 27
Infrared pupillometry (195) 77
Interferon β-1b (197) 51
Interleukin-1 (195) 51
Interleukin-2 (205) 47
Interleukines (197) 69
International Cooperative Ataxia Rating Scale (195) 149
Intracerebral hemorrhage (205) 29

Intracortical facilitation (198) 87
Intracortical inhibition (198) 87
Intraventricular hematoma (202) 35
In vitro antibody secretion (202) 77
IP-10 (195) 41
Ischemic heart disease (203–204) 7
Ischemic-vascular dementia (203–204) 153

Japanese (205) 47

Kallidin (202) 75
Kallikrein–kinin system (202) 75
Knowledge (200) 49

Labelled vinpocetine (203–204) 259
Lactic acidemia (201) 33
Lacunar infarctions (203–204) 53
Lacunar syndrome (197) 85
Late onset (195) 63
Leber hereditary optic neuropathy (205) 41
Left angular gyrus (203–204) 85
Leisure activities (201) 13
Leukoaraiosis (203–204) 159, (203–204) 169, (203–204) 221
Leukocytosis (202) 35
Leukodystrophy (195) 171
Lewy body (195) 85, (195) 153, (198) 97
Lewy pathology (195) 153
Lewy-related neurite (195) 153
Limbic encephalitis (201) 85
Limbic neurofibrillary tangle dementia (196) 63
Lipids (203–204) 195
Lipopolysaccharides (196) 1
Liver transplantation (195) 63
LM1 (195) 145
Longitudinal (203–204) 115
Longitudinal analysis (205) 41
Long-term (201) 13
Long-term potentiation (200) 11

Machado–Joseph disease (197) 37
Macrophage (195) 35
Macrophage/microglia (202) 13
Magnetic resonance imaging (195) 161, (197) 45, (199) 1, (199) 73, (205) 77
Magnetic resonance spectroscopy (198) 37
Magnetoencephalography (198) 51
Management (200) 49
MCP-1 (195) 41
MCP-3 (200) 43
Medical costs (203–204) 35
Medical education (198) 3
Memory (198) 79, (200) 11, (201) 53
Memory loss (201) 19
Meningitis (200) 63
Meningoencephalitis (200) 63
Mesencephalic tumor (197) 89
Metabolite T_2 (198) 37
Metaiodobenzylguanidine (MIBG) (195) 63
Methionine loading test (203–204) 121
Microglia (203–204) 273
Microsatellite (200) 43
Microscopic polyangiitis (195) 161
Microvasculature (203–204) 183
Microvessels (195) 51
Middle cerebral artery occlusion (199) 17
Midkine (200) 67
Mild cognitive impairment (201) 19, (203–204) 177
Miller Fisher syndrome (196) 1, (196) 41
Misery perfusion (205) 21
Mitochondrial disease (197) 63
Mitochondrial DNA (198) 31, (202) 85, (205) 41
Mitochondrial encephalomyopathies (202) 85
Mitotic segregation (205) 41
Mixed dementia (203–204) 3, (203–204) 11, (203–204) 29, (203–204) 125, (203–204) 177
Mixed pathologies (203–204) 29
Mixed-type dementia (203–204) 153
MMSE (203–204) 99
Mn poisoning (199) 93
Models, animal (198) 71
Mononuclear phagocytes (200) 33
Morphological subtypes (203–204) 153
Morphometry (196) 53
Mothers (200) 49
Motoneurons (195) 67, (198) 63
Motor deficit (203–204) 267
Motor neuron (195) 25
Motor neuron disease phenotype (195) 129
Motor restlessness (196) 33
Motor weakness (197) 79
Movement disorder (198) 21
Movement disorders (202) 59
MRI (195) 123, (197) 57, (197) 89, (198) 21, (199) 59, (199) 93, (203–204) 11, (203–204) 67, (203–204) 227, (203–204) 235, (203–204) 253
Mucopolysaccharidosis (195) 171
Multifrequency Doppler (203–204) 211
Multiple deletions (202) 85
Multiple sclerosis (195) 41, (195) 103, (197) 1, (197) 9, (197) 45, (197) 51, (197) 85, (198) 79, (199) 1, (200) 43, (200) 53, (201) 45, (201) 71, (202) 13, (202) 93, (205) 9, (205) 35, (205) 47, (205) 51
Multiple system atrophy (195) 123, (197) 37, (199) 31, (200) 1, (200) 79
Muscle (195) 11
Muscle MRI (199) 45
Mutation (195) 129, (200) 85
Myasthenia gravis (202) 5, (202) 77
Myelitis (197) 57
Myoclonic involuntary movement (199) 93
Myoclonus (202) 59
Myosin (195) 11
Myotonic dystrophy type 1 (201) 59

N-acetylaspartate (198) 37
N-Acetylaspartate (199) 73
Natural history (203–204) 53
Nerve growth factor (NGF) (198) 63
Nerve injury (202) 69
Nerve recovery (202) 69
Neurofibrillary tangle (195) 85
Neurofilament (196) 53
Neurological manifestations (203–204) 67
Neurologic services (200) 75
Neurology (203–204) 81
Neurology training (198) 3
Neuromuscular disorders (202) 77
Neuromyelitis optica (197) 57
Neuronal loss (200) 19
Neuronopathic and non-neuronopathic phenotypes (199) 39
Neuropathy (195) 47
Neuropsychological test (203–204) 103
Neuropsychology (203–204) 11, (203–204) 17, (203–204) 115, (203–204) 221

Neurosarcoidosis (205) 77
Neurotrophin (198) 63
New onset seizures (202) 29
Nicotinic acetylcholine receptors (203–204) 131
Nitric oxide (198) 9
Nociception (205) 59
Non-clinical studies (203–204) 259
Non-invasive autonomic testing (195) 77
Norepinephrine (200) 1
Normal (195) 1
Normal-appearing white matter (197) 45
Notch3 (203–204) 77
Novel mutations (201) 39
Nuclei (203–204) 165

Observational clinical study (203–204) 137
Oddball paradigm (205) 35
Oligodendrocyte (197) 9
Oligodendrocytes (203–204) 277
Optic neuritis (197) 57
Orthostatic hypotensive (200) 1
Outcome (198) 21
Overlap syndrome (205) 65
Oxidative modification of LDL (203–204) 195
Oxidative stress (196) 45, (203–204) 195

p75NTR (195) 35
Pain perception (196) 81
Paired TMS (198) 87
Paraneoplastic limbic encephalitis (201) 9
Parasympathetic (200) 1
Parasympathetic nervous system (195) 77
Parkinsonism (197) 89, (198) 97, (200) 79, (202) 59
Parkinson's disease (195) 167, (196) 33, (199) 25, (199) 31
Partner (201) 13
Pathogenesis (203–204) 3
Pathology (199) 1
PECAM-1 (200) 43
Perforant pathway (195) 85
Periodic limb movements (198) 71
Peripheral injury (201) 79
Peripheral nerve (195) 35
Peripheral nervous system disorders (196) 1
PET (199) 79, (200) 27, (203–204) 259
Phenotypic heterogeneity (197) 63
Physicians (198) 3
Pick's disease (196) 63
Plaques (197) 9
Plasmapheresis (201) 85
Platelets (198) 9, (203–204) 189
POEMS (195) 47
Point mutation (197) 63
Polymorphism (200) 43, (205) 47
Polymyositis (205) 65
Positron emission tomography (199) 67, (200) 79, (205) 21, (205) 77
Positron emission tomography (PET) (203–204) 247
Posterior column (197) 73
Postpartum (205) 29
Post-polio syndrome (PPS) (205) 9
Postural tremor (202) 59
Practice (200) 49
Pretangle (196) 71
Primary care (200) 75
Primary progressive (199) 1
Process dissociation procedure (198) 79
Prognosis (196) 37, (199) 1
Progression (195) 153
Progressive disease (197) 1
Progressive supranuclear palsy (199) 31, (199) 67
Prosopagnosia (196) 71
Protease (196) 9
Psychometrics (201) 19
Psychosocial effects (201) 13
Public health (198) 3
Pupillary light reflex (195) 77
Pyridoxine (203–204) 121
Pyruvate dehydrogenase complex deficiency (201) 33

q-space (203–204) 235
QTc interval (199) 31
QT-dispersion (201) 59
Quality of life (205) 51
Quantification of neuronal activity (198) 51
Quantitative PCR (200) 53
Quantitative sensory testing (205) 59

Radiation-induced apoptosis (199) 39
Rat (198) 43, (199) 17, (202) 69, (203–204) 263, (203–204) 267, (203–204) 277
Rating scale (203–204) 241
Rats (198) 71, (200) 33
Recurrence (202) 65
Reliability (203–204) 109
Remembered saccade (195) 25
Restless legs syndrome (196) 33, (198) 71
Reverse immunogenetics (201) 9
Ribavirin (200) 63
Riley–Day-syndrome (196) 81
Risk factors (198) 31, (201) 19, (203–204) 73, (203–204) 253, (205) 15, (205) 71
Rivastigmine (203–204) 141

α-Synuclein (195) 85, (195) 153
Sandhoff disease (195) 129
Sarcoidosis (205) 77
SCA (200) 19
SCA6l (195) 149
Scavenger receptor class B type I (196) 45
SCD (195) 149
Scleroderma (205) 65
Screening test (203–204) 109
Senile involutive cortical changes (195) 1
Serotonin (198) 9
Sertraline (203–204) 227
Severe headache (200) 63
Sex hormone binding globulin (195) 67
Silent infarcts (203–204) 67
Silent period (199) 55
Silent strokes (203–204) 211
Single-photon emission tomography (205) 21
Single stroke (203–204) 85
Sjögren syndrome (197) 79
Skeletal muscle (202) 85
Sleep (198) 71
Sleep-disordered breathing (195) 11
Small cell lung carcinoma (201) 9
Small vessel disease (203–204) 17, (203–204) 77, (203–204) 153, (203–204) 253
Snoring (195) 11
Soft palate (195) 11
Somatic point mutations (202) 85

Somatosensory evoked field (198) 51
Sp1 (197) 27
Spastic paraparesis (195) 71
Spastin (201) 65
SPECT (203–204) 199, (203–204) 215
Spectroscopy (199) 73
Spectroscopy, near-infrared (205) 15, (205) 71
SPECT scan (202) 29
SPG4 (201) 65
Spinal cord atrophy (195) 71
Spinal cord injury (200) 33
Spinal cord transection (198) 63
Spinocerebellar ataxia 1 (197) 37
Spinocerebellar ataxia type 2 (198) 87, (201) 53
Spinocerebellar tract (197) 73
Staging (195) 153
Statistical parametric mapping (203–204) 199
Stem completion (198) 79
String vessels (203–204) 165
Stroke (195) 117, (196) 27, (196) 91, (197) 85, (199) 73, (202) 53, (202) 65, (202) 75, (203–204) 7, (203–204) 49, (203–204) 67, (203–204) 77, (203–204) 115, (203–204) 221, (203–204) 277
Stroke management (199) 49
Stroke onset (199) 49
Stroke prevention (203–204) 121
Stroke severity (201) 1
Stroke subtypes (195) 117
Subcortical features (203–204) 99
Subcortical hyperintensities (203–204) 227
Subcortical vascular dementia (203–204) 17, (203–204) 91, (203–204) 199, (203–204) 263
Subcortical vascular lesions (203–204) 153
Subdural EEG (202) 43
Sub-Saharan Africa (200) 75
Substantia nigra (198) 97
Subthalamic nucleus (195) 167
Suicidal Hanging (198) 21
Superoxide dismutase (198) 17
Supplementary motor area (202) 43
Sympathetic (200) 1
Sympathetic dysfunction (196) 81
Sympathetic nervous system (195) 77
Synapse (200) 11

Target tissue (202) 69
Tau (195) 85, (196) 71
Tauopathy (200) 85
Tau protein (200) 85, (203–204) 207
Tendon reflex (199) 89
Testosterone (195) 67
Th1 (196) 21, (201) 45
Th2 (201) 45
Thalamus (203–204) 91
Therapeutics (199) 1
Thermal pain (205) 59
Thiamine pyrophosphate (201) 33
Thiamine treatment (201) 33
Threshold of muscle twitch (198) 51
Thrombomodulin (203–204) 189
Th1/Th2 immune response (200) 53
Thymectomy (202) 77
Thymus (202) 77
Tinnitus (196) 77
Tissue plasminogen activator (202) 35
Tissue transglutaminase (203–204) 207
α-Tocopherol (203–204) 195
Transcranial Doppler (195) 139
Transcranial Doppler ultrasound (205) 29
Transcranial magnetic stimulation (198) 87
Transforming growth factor-β (200) 33
Transient ischemia (203–204) 267
Transplantation (199) 17
Transthyretin (198) 93
Treatment delays (199) 49
T_1 relaxation time (197) 45
Trial design (203–204) 41
Tubulin (196) 53
Tumor necrosis factor (197) 69
Tumor necrosis factor-alpha (201) 59
Tumor necrosis factor (TNF) (195) 51
Twinkle (201) 39

Ultrasonography, Doppler, Transcranial (205) 15
Ultrasonography, Doppler, transcranial (205) 71
Utrophin (197) 27
Utrophin promoter (197) 27

Vaccination, adverse effects (195) 111
Validity (203–204) 109
Varicella-zoster virus (195) 111
Vascular cognitive impairment (203–204) 11, (203–204) 23, (203–204) 99, (203–204) 147, (203–204) 241
Vascular dementia (196) 63, (203–204) 3, (203–204) 7, (203–204) 11, (203–204) 23, (203–204) 29, (203–204) 35, (203–204) 41, (203–204) 57, (203–204) 67, (203–204) 73, (203–204) 125, (203–204) 131, (203–204) 141, (203–204) 147, (203–204) 173, (203–204) 177, (203–204) 195, (203–204) 207, (203–204) 215, (203–204) 235
Vascular depression (203–204) 227
Vascular malformation (196) 91
Vascular pathology (203–204) 159
Vasculitis (197) 57, (205) 29
Vasodilatory (205) 21
Vasomotor reactivity (205) 15
Venous collagenosis (203–204) 159
Ventricular dilatation (202) 35
Ventricular function (198) 43
Ventricular late potentials (201) 59
Vertigo (196) 77
Vinpocetine (203–204) 259
Vitamin (202) 65
Vitamin B_{12} (203–204) 121
Vitamin E (198) 25
Vitamins (203–204) 121
Vocal cord paralysis (197) 37
Voxel-based analysis (199) 79
Voxel-by-voxel analysis (199) 67
Voxel-by-voxel statistics (200) 27

Wallerian degeneration (196) 9
Weakness (200) 63
Wegener's granulomatosis (195) 161
West Nile Virus (200) 63
White matter (203–204) 221, (203–204) 241
White matter changes (195) 171
White matter disease (195) 111
White matter lesion (203–204) 199
White matter lesions (203–204) 253
Work (201) 13
Working memory (195) 25

Zinc (195) 1
Z-VAD (199) 17